

jc584 U.S. PTO

UTILITY PATENT APPLICATION TRANSMITTAL

Only for nonprovisional applications under 37 CFR § 1.53(b))

Attorney Docket No.

230018.401C1

First Inventor or Application Identifier

Max Cynader

Title

GENE SEQUENCES ASSOCIATED WITH NEURAL
PLASTICITY AND METHODS RELATED THEREOF

Express Mail Label No.

EL251274450US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO:

Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 202311. ☒ General Authorization Form & Fee Transmittal
(Submit an original and a duplicate for fee processing)2. ☒ Specification [Total Pages] **59**
(preferred arrangement set forth below)
- Descriptive Title of the Invention
- Cross References to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to Microfiche Appendix
- Background of the Invention- Brief Summary of the Invention
- Brief Description of the Drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the Disclosure3. ☒ Drawing(s) (35 USC 113) [Total Sheets] **26**4. Oath or Declaration [Total Pages] **4**
a. ☐ Newly executed (original or copy)
b. ☒ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)i. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting
inventor(s) named in the prior application,
see 37 CFR 1.63(d)(2) and 1.33(b)5. ☐ Incorporation By Reference (useable if box 4b is checked)
The entire disclosure of the prior application, from which a copy
of the oath or declaration is supplied under Box 4b, is
considered to be part of the disclosure of the accompanying
application and is hereby incorporated by reference therein.6. ☐ Microfiche Computer Program (Appendix)7. Nucleotide and Amino Acid Sequence Submission
(if applicable, all necessary)

- a.
- ☐
- Computer-Readable Copy
-
- b.
- ☐
- Paper Copy (identical to computer copy)
-
- c.
- ☐
- Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

- 8.
- ☐
- Assignment Papers (cover sheet & document(s))
-
- 9.
- ☐
- 37 CFR 3.73(b) Statement (when there is an assignee)
- ☐
- Power of Attorney
-
- 10.
- ☐
- English Translation Document (if applicable)
-
- 11.
- ☐
- Information Disclosure Statement (IDS)/PTO-1449
- ☐
- Copies of IDS Citations
-
- 12.
- ☐
- Preliminary Amendment
-
- 13.
- ☒
- Return Receipt Postcard
-
- 14.
- ☐
- Small Entity Statement(s)
- ☒
- Statement filed in prior application, Status still proper and desired
-
- 15.
- ☐
- Certified Copy of Priority Document(s) (if foreign priority is claimed)
-
- 16.
- ☒
- Other:
- Certificate of Express Mail
-
- Check No. for \$1,218
-
- Associate Power of Attorney on
-
- 08/224.621(+1)
-
- Petition for Extension of Time (+2)
-
- General Authorization on 08/224.621

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment

☒ Continuation ☐ Divisional ☐ Continuation-In-Part (CIP) of prior Application No.: 08/224,621Prior application information: Examiner Bruce CampbellGroup / Art Unit 1632☐ Claims the benefit of Provisional Application No. _____

CORRESPONDENCE ADDRESS

David D. McMasters
Seed and Berry LLP
6300 Columbia Center
701 Fifth Avenue
Seattle, Washington 98104-7092
(206) 622-4900 phone
(206) 682-6031 fax

Respectfully submitted,

TYPED or PRINTED NAME Jane E. R. PotterSIGNATURE April 28, 1999

U:\LizM\mwr\Cynader230018.0005

REGISTRATION NO. 33,332Date April 28, 1999

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants or Patentees: Max Cynader and
Shiv Prasad

Attorney's Docket No: 230018.401

Serial or Patent No.: 08/224,621

Filed or Issued: April 5, 1994

For: GENE SEQUENCES ASSOCIATED WITH NEURAL PLASTICITY
AND METHODS RELATED THERETO

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
 (37 C.F.R. §§ 1.9(f) AND 1.27(b)) --

MULTIPLE INDEPENDENT INVENTORS

As the below-named inventors, we declare that we qualify as independent inventors as defined in 37 C.F.R. § 1.9(c) for purposes of paying reduced fees under 35 U.S.C. §§ 41(a) and 41(b) with regard to the invention entitled:

Max Cynader and
Shiv Prasad

as described in:

- ☐ the specification filed herewith.
- ☒ application Serial No. 08/224,621,
 filed April 5, 1994.
- ☐ Patent No. _____, issued _____.

We have not assigned, granted, conveyed or licensed, and are under no obligation under contract or law to assign, grant, convey or license, any rights in the invention to any person who could not be classified as an independent inventor under 37 C.F.R. § 1.9(c) if that person had made the invention or to any concern which would not qualify as a small business concern under 37 C.F.R. § 1.9(d) or a nonprofit organization under 37 C.F.R. § 1.9(e).

Each person, concern or organization to which we have assigned, granted, conveyed or licensed, or are under an obligation under contract or law to assign, grant, convey or license, any rights in the invention is listed below:

- ☐ no such person, concern or organization
- ☐ persons, concerns or organizations listed below*

05301507.043899
 662240/2510360

*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to his/its status as a small entity. (37 C.F.R. § 1.27)

FULL NAME _____

ADDRESS _____

- ☐ individual
☐ small business concern
☐ nonprofit organization



FULL NAME _____

ADDRESS _____

- ☐ individual
☐ small business concern
☐ nonprofit organization

We acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earlier of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 C.F.R. § 1.28(b))

We declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that the making of willfully false statements and the like is punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Max Cynader	// Shiv Prasad	//
NAME OF INVENTOR	NAME OF INVENTOR	NAME OF INVENTOR
		
SIGNATURE	SIGNATURE	SIGNATURE
Sept 20 / 94	June 20 1994	
DATE	DATE	DATE

DescriptionGENE SEQUENCES ASSOCIATED WITH
NEURAL PLASTICITY AND METHODS RELATED THERETO

5

Technical Field

The present invention relates to newly-identified polynucleotide sequences capable of conferring neural plasticity, and to the complete gene sequences and polypeptides associated therewith and to uses thereof.

10

Background of the Invention

Identification and sequencing of genes is a major goal of modern scientific research. By identifying genes and determining their sequences, scientists have, for example, been able to make large quantities of valuable human "gene products." These include human insulin, interferon, Factor VIII, tumor necrosis factor, human growth hormone, tissue plasminogen activator, and numerous other compounds. Additionally, knowledge of gene sequences of the central and peripheral nervous systems can provide the key to treatment or cure of genetic diseases, degenerative disorders, neural damage or regrowth and learning disorders.

15

20

25

30

35

Genes are the basic units of inheritance. Each gene is a string of connected bases called nucleotides. Most genes are formed of deoxyribonucleic acid, DNA. (Some viruses contain genes of ribonucleic acid, RNA.) The genetic information resides in the particular sequence in which the bases are arranged. A sequence of nucleotides is often called a polynucleotide or an oligonucleotide. A triplet of nucleotides, called a "codon," in DNA codes for each amino acid or signals the beginning or end of the message, called an "anticodon." The term codon is also used for the corresponding (and

complementary) sequences of three nucleotides in the mRNA into which the original DNA sequence is transcribed.

Like genes, polypeptides are built from long strings of individual units. These units are termed
5 "amino acids." The polynucleotide of a gene tells the cell the sequence in which to arrange the amino acids to make the polypeptide encoded by that gene. In general, chains of up to about 200 amino acids are called "polypeptide subunits" or "polypeptides."

10 Generally, enzymes in the cell transcribe the DNA of the gene into a transient RNA copy, called messenger RNA or mRNA. The mRNA, in turn, can be translated into a polypeptide by the cell. This entire process is called "gene expression," and the polypeptide
15 is the "gene product." Scientists have discovered how to reverse the transcription process and copy mRNA back into DNA using an enzyme called "reverse transcriptase." The resulting sequence is called "complementary DNA" or "cDNA." When substantially all of the mRNA from a cell or
20 a tissue is converted to cDNA and cloned into multiple copies of a recombinant vector to allow replication and manipulation in the laboratory, the resulting series of sequences are referred to collectively as a "cDNA library."

25 The various types of genes include those which code for polypeptides, those which are transcribed into RNA but are not translated into polypeptides, and those whose functional significance does not demand that they be transcribed at all. Most genes are found on large
30 molecules of DNA located in chromosomes. Double-stranded cDNA carries all the information of a gene. Each base of the first strand is joined to a complementary base, or "hybridized," in the second strand. The linear DNA molecules in chromosomes have thousands of genes
35 distributed along their length. Chromosomes include both coding regions, which code for polypeptides, and noncoding

09301507 042399
668240 20570660

regions; the coding regions represent only about three percent of the total chromosome sequence.

An individual gene has regulatory regions including a promoter that directs the expression of the gene, a coding region that may code for a polypeptide, and a termination signal. The regulatory DNA sequence is usually a noncoding region that determines if, where, when, and at what level a particular gene is expressed.

The coding regions of many genes are discontinuous, with coding sequences, or "exons," alternating with noncoding regions, or "introns." The final mRNA copy of the gene does not include these introns (which can be much longer than the coding region itself), although it does contain certain untranslated regions that usually do not code for the polynucleotide gene product. Untranslated sequences at the beginning and end of the mRNA are known as 5'- and 3'-untranslated regions, respectively. This nomenclature reflects the orientation of the nucleotide constituents of the mRNA.

A cDNA is a DNA copy of a messenger RNA, which contains all of the exons of a gene. The cDNA can be thought of as having three parts: an untranslated 5' leader, an uninterrupted polypeptide-coding sequence, and a 3' untranslated region. The untranslated leader and trailing sequences are important for initiation of translation, mRNA stability, and other functions. The untranslated leader and trailing sequences are called 5'- and 3'-untranslated sequences, respectively. The 3' untranslated sequence is usually longer than the 5'- untranslated leader, and can be longer than the polypeptide-coding sequence. The untranslated regions typically have many, randomly-distributed stop codons, and do not display the nonrandom base arrangements found in coding sequences. The 5'- untranslated sequence is relatively short, generally between 20 and 200 bases. The 3'-untranslated sequence is often many times longer, up to several thousand bases.

09301507 042899

5 The translated or coding sequence begins with a translational start codon (AUG or GUG) and ends with a translational stop codon (UAA, UGA, or UAG). Generally, translation begins at the first "start" codon on the mRNA and proceeds to the first "stop" codon. Coding sequences can be distinguished by their nonrandom distribution of bases; numerous computer algorithms have been developed to distinguish coding from noncoding regions in this way.

10 Human DNA differs from person to person. No two persons (except perhaps identical twins) have identical DNA. While the differences, called allelic variations or polymorphisms, are slight on a molecular level, they account for most of the physical and other observable differences between individuals. It has been estimated
15 that approximately 14 million sequence polymorphism differences exist between individuals.

20 The ability of one strand of DNA to attach or hybridize to a complementary strand has already been exploited for several purposes. For example, small pieces of DNA (15 to 25 base pairs long) can be made which will hybridize to longer strands of DNA which have a complementary sequence. These short "primers" can be selected such that they hybridize to a specific, unique location on the longer strand. Once the primers have
25 hybridized to their target on the DNA, the polymerase chain reaction (PCR) can be employed to generate millions of copies of (or amplify) the particular segment of DNA between the locations to which two primers are bound. Briefly, this technique allows amplification of a DNA
30 region situated between two convergent primers, using oligonucleotide primers that hybridize to opposite strands. Primer extension proceeds inward across the region between the two primers, and the product of DNA synthesis of one primer serves as a template for the other
35 primer. Repeated cycles of DNA denaturation, annealing of primers, and extension result in an exponential increase

09301507 0510560

in the number of copies of the region bounded by the primers.

Similarly, a labeled segment of single-stranded DNA can be hybridized to a longer DNA sequence, such as a chromosome, to mark a specific location on the longer sequence. Segments of DNA 50 bases long or longer that hybridize to a unique DNA location in the human genome are extremely unlikely to hybridize elsewhere in the human genome. Because coding regions comprise such a small portion of the human genome, identification and mapping of transcribed regions and coding regions of chromosomes is of significant interest.

Previous studies have shown that relatively few brain mRNAs with regionally heterogeneous distributions are of sufficient abundance to permit detection of their corresponding cDNA clones by differential colony screening. Differential screening of cDNA libraries with labeled first strand cDNAs synthesized from unfractionated RNA can only detect clones representing highly abundant mRNA species (0.1% abundance or more). Current evidence indicates that many mRNA species that are known to be of biological importance (such as transcription and growth factors for instance) are present only in low abundance. Thus, detection of low abundance clones is of obvious importance particularly for use in gene therapy in delicate neural tissues.

The search for treatments for neural degenerative disorders and injury to neural tissues has been relatively unsuccessful. The term "degenerative", as applied to diseases of the nervous system, is used to designate a group of disorders in which there is a gradual, generally symmetric, relentlessly progressive wasting away of neurons, for reasons still unknown. Many of the conditions so designated depend on genetic factors and thus appear in more than one member of the same family. This general group of diseases is therefore frequently referred to as "heredodegenerative." A number

of other conditions, not apparently differing in any fundamental way from the hereditary disorders, occur only sporadically, i.e., as isolated instances in a given family.

5 It is a characteristic of the degenerative diseases that they begin insidiously and run a gradual progressive course which may extend over many years. The earliest changes may be so slight that it is frequently impossible to assign any precise time of onset. However, 10 as other gradually developing conditions, the patient may give a history implying an abrupt appearance of the disability. This is particularly likely to occur if there has been an injury, or if some other dramatic event has taken place in the patient's life, to which illness might 15 conceivably be related. In such a case, skillfully taking of the history may bring out that the patient or family had suddenly become aware of the condition which had, in fact, already been present for some time but had passed unnoticed. Whether trauma or other stress may bring on or 20 aggravate one of the degenerative diseases is still a question that cannot be answered with certainty. From all that is known, it would seem highly improbable that this could happen. In any event, it must be kept in mind that the disease processes under discussion, by their very 25 nature, developed spontaneously without relation to external factors.

Family history of degenerative nervous diseases is a significant feature of this class of diseases. Another significant feature is that, in general, their 30 ceaselessly progressive course is uninfluenced by all medical or surgical measures. Dealing with a patient with this type of illness is often, therefore, an anguishing experience for all concerned. Its symptoms can often be alleviated by wise and skillful management.

35 A striking feature of a number of disorders of this class is the almost selective involvement of the anatomically or physiologically related systems of

neurons. This is clearly exemplified in amyotrophic lateral sclerosis, in which the process is almost entirely limited to cortical and spinal motor neurons, and in certain types of progressive ataxia, in which the Purkinje
5 cells of the cerebellum are alone affected. Many other examples could be cited in which certain neuronal systems disintegrate, leaving others perfectly intact.

An important group of degenerative diseases has therefore been called "system diseases," and many of these
10 are strongly hereditary. It must be realized, however, that selective involvement of neuronal systems is not exclusively a property of the degenerative group, since several disease processes of known cause have similar circumscribed effects on the nervous system. Diphtheria
15 toxin, for instance, selectively attacks the myelin of the peripheral nerves. Another example is a special vulnerability of the Purkinje cells of the cerebellum to hyperthermia. On the other hand, several of the conditions included among degenerative diseases are
20 characterized by the pathologic changes that are diffuse and unselective. These exceptions nevertheless do not detract from the importance of affection of particular neuronal systems as a distinguishing feature of many of the diseases under discussion.

25 Learning disorders, ranging from dyslexia to mental retardation, can be equally devastating. However, in these circumstances, instead of the slow degeneration of the brain function, the afflicted party struggles with an inability to comprehend and/or retain information. The
30 broad spectrum of learning disorders may arise as a result of heredity or injury. For example, it is known that there are specific areas of cortex in the left hemisphere of the brain that are specifically active during reading, and it is known that damage to these areas results in
35 specific loss of reading capabilities. A review of specific cortical areas involved in reading and language is found in Mayeux, E. and Kandel, E.R., Chapter 54 (pp.

00301507 042299
662240 205 F0660

839-851) in Kandel, E.R., Schwartz, J.H., and Jessell, T.M., *Principles of Neural Science*, 3d ed., Elsevier Press, N.Y., 1991, incorporated herein by reference.

Additional background information and definitions for scientific terms can be found in the literature. See, for example, Rieger et al., *Glossary of Genetics, Classical and Molecular*, 5th ed., Springer-Verlag, New York, 1991. The contents of this and other publications cited in the specification are incorporated by reference herein.

The present invention discloses novel compositions and methods for conferring neural plasticity to regions of the brain in need thereof, and further provides other related advantages.

Summary of the Invention

Briefly stated, the present invention provides compositions and methods for conferring neural plasticity to cells of the peripheral and central nervous systems.

One aspect of the invention includes cDNA libraries isolated from a visual cortex of a kitten about 24-35 days old.

Another aspect of the invention includes cDNA libraries comprising polynucleotides differentially expressed between polynucleotides isolated from a visual cortex of a kitten about 24-35 days and polynucleotides isolated from a visual cortex of an adult feline.

Another aspect of the invention includes cDNA libraries comprising differentially expressed between polynucleotides isolated from a visual cortex of a dark-reared adult feline and polynucleotides of a visual cortex of an adult feline.

Another aspect of the invention includes cDNA libraries comprising polynucleotides isolated from the visual cortex of a dark-reared adult feline.

09301507.042899
668240/057060

Yet another aspect of the invention includes compositions comprising an isolated polynucleotide having a sequence designated as one of: SEQ. ID. NOS.: 1-132 or allelic variation thereof or complementary sequence thereto, or portion thereof at least 15 nucleotides in length.

Yet another aspect of the invention includes isolated nucleic acid molecules comprising human genes capable of hybridizing to a sequence designated as any one of SEQ. ID. NOS.: 1-93, 120-132, or to a sequence complementary thereto, under hybridization conditions sufficiently stringent to require at least about 80% base pairing.

Another aspect of the invention includes antisense polynucleotides and triple helix probes capable of blocking expression of a gene product.

Another aspect of the invention includes constructs capable of directing the expression of any one of the disclosed nucleic acid molecules of the invention.

Yet another aspect of the invention includes methods of treating warm-blooded animals for neurological disorders, by administering to a warm-blooded animal a therapeutically effective amount of a composition comprising a polynucleotide of the present invention, in combination with a pharmaceutically acceptable carrier or diluent such that said neurological disorder is treated.

Another aspect of the invention includes methods of treating learning disorders by administering a warm-blooded animal a therapeutically effective amount of a composition comprising a polynucleotide of the present invention in combination with a pharmaceutically acceptable diluent or carrier, such that the learning disorder is treated.

Another aspect of the invention includes methods of enhancing learning and memory of warm-blooded animals, comprising administering an effective amount of a

0510560

polynucleotide of the present invention in combination with a pharmaceutically acceptable carrier or diluent, such that learning and memory are enhanced.

Yet another aspect of the invention includes a
5 pharmaceutical composition, comprising any one of the polynucleotides of the present invention in a pharmaceutically acceptable diluent or carrier.

These and other aspects of the present invention will become evident upon reference to the following
10 detailed description and attached drawings. In addition, various references are set forth which describe in more detail certain procedures and/or compositions, and are hereby incorporated by reference in their entirety.

15 Brief Description of the Drawings

Figure 1 depicts the scheme of the strategy employed in the preparation of a 30-day-old kitten visual cortex specific subtracted probe outlined in the examples.

Figure 2 depicts an autoradiogram showing an
20 example of a subtractive-hybridization screening of a 30 day old kitten visual cortex cDNA library. The 12,000 cDNA clones constructed were spread on 12 Luria broth plates containing 50 µg of ampicillin per ml at a density of 1000 clones per plate. The colonies were transferred
25 to nylon membranes and lysed *in situ*. The filters were hybridized with the 30-day-old kitten visual cortex subtracted probe as described in materials and methods. The clones irrespective of their signal intensity were individually isolated.

30 Figure 3 depicts northern blot analysis with RNAs (10 µg) from the 30-day-old kitten visual cortex and adult cat visual cortex probed with riboprobes derived from eight of the 200 purified cDNA clones. Hybridization was carried out with the probes indicated below;
35 (a) pKVC6, (b) pKVC79, (c) pKVC80, (d) pKVC82, (e) pKVC90, (f) pKVC100, (g) pKVC108 and (h) pKVC110.

Figure 4 depicts a diagram of possible cellular location of the identifiable proteins which are enriched in the 30 day kitten visual cortex.

Figure 5 depicts sequence listings for SEQ. ID.
5 NOS.: 1-132.

Detailed Description of the Invention

This invention is generally directed to several cDNA libraries, specific polynucleotides, allelic variations thereof or complementary sequences thereto, or portions thereof at least 15 nucleotides in length, and their associated gene sequences and polypeptides, all of which are capable of conferring the characteristic of neural plasticity. These nucleic acid sequences and polypeptides have a multitude of uses, including as markers or probes, i.e., in chromosome mapping, and for use in gene therapy.

One aspect of the present invention provides cDNA libraries constructed from feline visual cortices using any one of a variety of techniques, including, for example, a cDNA library kit available from Stratagene Corporation. Feline visual cortices are easily identifiable by observation and may be isolated and processed as set forth in the Examples below.

Those polynucleotides particularly suitable for conferring neural plasticity are then isolated from the libraries by selecting those polynucleotides which appear either uniquely, or in much greater relative abundance, in the critical stage kitten when compared to the adult feline. In the context of the present invention, these sequences are referred to as "differentially expressed sequences." Selection of differentially expressed sequences may be accomplished using any one of several techniques, including, for example, differential screening, differential display polymerase chain reaction ("PCR"), and subtractive hybridization. See Innis et al., *PCR Protocols: A Guide to Methods and*

Applications, Academic Press, Inc., 1990. Preferably, the sequences may be selected using any suitable technique capable of detecting polynucleotides present as low as 0.01% of the total mRNA population, including subtractive
5 hybridization as described in detail in Sieve and St. John, *Nucl. Acids Res.* 16:10937, 1988, incorporated herein by reference.

In the context of the present invention, "neural plasticity" refers to the ability of a cell to make a long
10 term alteration of its circuitry and functionality in response to new inputs, as well as the ability of neural tissue to recover from injury by reorganizing its function to compensate for partial destruction of tissue or loss of function caused by degenerative disorders. Thus, neural
15 plasticity refers to both increased modifiability, in the sense of being able to learn an altered circuitry in response to specific experiences, and also to increase the capacity to repair in the sense of being able to reorganize following various forms of neural damage.

In the context of the present invention, "critical stage kitten" refers to a feline when its visual cortex is at the height of a critical stage. The term "critical stage" refers to the point in neural development when the neurons are at or near the height of neural
20 plasticity. Generally, this occurs when the kitten is between about 24-35 days old; typically, when it is between about 26-32 days old; and preferably when it is about 28 days old.

In the context of the present invention, an
30 "adult feline" refers to a feline generally at least four months of age, preferably at least six months of age.

In another aspect of the invention, cDNA libraries are constructed from the visual cortex of a dark-reared feline using the same techniques described
35 above. In the context of the present invention, the term "dark-reared feline" refers to felines that have been reared from before the age of eye opening (8-12 days old)

to at least four months of age, with no more than 1 hour continuous exposure to light; preferably with no more than 10 minutes continuous exposure to light; and, even more preferably, these felines have never been exposed to light. These felines are characterized by delayed development of the visual cortex. In other words at four months, their cortex remains at a critical stage, exhibiting a high degree of neural plasticity.

In a preferred embodiment of the present invention, a first set of cDNA libraries are constructed from the differentially expressed sequences between the critical stage kittens and the adult felines. A second set of cDNA libraries are constructed from the differentially expressed sequences between the dark-reared felines and the adult felines. Then, using any one of several techniques, the commonly expressed sequences are extracted and form the preferred cDNA libraries. Suitable techniques include any of the techniques described above. Preferably, subtractive probes, formulated from the second cDNA libraries, are used to screen the first libraries. In the context of the present invention, these commonly expressed sequences will also be referred to as "differentially expressed sequences."

The differentially expressed sequences comprising any one of the above cDNA libraries are verified using any one of several techniques, including Northern blot hybridization, described in detail in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1989, incorporated herein by reference. The differentially expressed sequences which are generally at least two-fold enriched (based on band intensity comparisons), typically at least three-fold enriched, and preferably at least four-fold enriched are likely to be truly representative of the differentially expressed sequences. Some sequences represent mRNAs of abundance too low to be detected on the total cellular RNA blots. In these circumstances, antisense riboprobes are

used to detect transcripts on the blots containing poly (A) RNA or total RNA from the first group. Alternatively, quantitative polymerase chain reaction may be used to detect or verify differences in expression.

5 In order to sequence any specific cDNA, it generally is isolated and purified from all the other sequences. This can be accomplished using any one of several techniques, including alkaline lysis described in detail in Sambrook et al., *Molecular Cloning: A Laboratory*
10 *Manual*, Cold Spring Harbor Laboratory, 1989. Briefly, in one embodiment, a bacterial colony containing the cDNA of interest is identified and further amplified. Once cDNA is amplified from the mixed clone library, it can be used as a template for further procedures such as nucleotide
15 sequencing.

The sequences, constructs, vectors, clones, and other materials comprising the present invention can advantageously be in the enriched or isolated form. Within the context of the present invention, "enriched"
20 means that the concentration of the material is at least about 2, 3, 4, 10, 100, or 1000 times its natural concentration, for example, advantageously 0.01% by weight, preferably at least about 0.1% by weight. Enriched preparations of about 0.5%, 1%, 5%, 10%, and 20%,
25 by weight, are also contemplated.

Within the context of the present invention, the term "isolated" requires that the material be removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally
30 occurring polynucleotide present in a living animal is not isolated, but the same polynucleotide, separated from some or all of the coexisting materials in the natural system, is isolated.

It is also advantageous that the sequences be in
35 purified form. Within the context of the present invention, the term "purified" does not require absolute purity; rather, it is intended as a relative definition.

09301507-04289
668240-0510660

668240" 20510E60

The cDNA clones are not naturally occurring as such, but rather are obtained via manipulation of a partially purified naturally occurring substance (messenger RNA). The conversion of mRNA into a cDNA library involves the
5 creation of a synthetic substance (cDNA) and pure individual cDNA clones can be isolated by screening the library with specific probes. Thus, creating a cDNA library from messenger RNA and subsequently isolating individual clones from that library results in a single
10 clone in substantially pure form.

One of ordinary skill in the art will appreciate that the human polynucleotides may be identified and isolated given the feline sequences. Human sequences share at least 80% homology with feline sequences. When
15 the comparison is extended to the amino acid level, sequence identity is increased to 92%. Once the corresponding human sequences have been identified and isolated, the associated polypeptides may be identified and produced.

20 Polynucleotides of the present invention include the polynucleotides depicted by the specific sequences set forth in the Sequence Listing and designated SEQ ID NO: 1 - SEQ ID NO: 132. In the context of the present invention, the term "polynucleotide" is intended to refer
25 to the polynucleotides represented by SEQ. ID. NOS.: 1-132, complementary sequences thereto, allelic variations thereof, or portions thereof, and cDNA clones related thereto. These polynucleotides are also included in the differentially expressed sequences described in detail
30 above.

In addition to the claims to individual polynucleotides, it is intended that the present disclosure also supports claims to numerical subgroupings. Thus, subgroupings of 50 polynucleotides, and their
35 corresponding sequences, are contemplated as being within the scope of this invention, as are subgroupings of 5, 10, 25, and 100 polynucleotides.

Knowledge of the sequences of the polynucleotide of the present invention permits routine isolation and sequencing of the complete coding sequence of the corresponding gene. The complete coding sequence is present in a full-length cDNA clone as well as in the gene coding region on the genomic clones. Therefore, each partial polynucleotide of the present invention corresponds to a cDNA from which it was derived, a complete genomic gene sequence, a polypeptide coding region, and a polypeptide or amino acid sequence encoded by that region.

The polynucleotides of the present invention are generally of sufficient length to effect preliminary identification and exact chromosome mapping. Accordingly, the polynucleotides disclosed herein are generally at least 50 base pairs in length, typically in the range of about 90 to 500 base pairs in length, and preferably in the range of about 150 to 500 base pairs in length. The length is ultimately determined by the quality of sequencing data and the length of the cloned cDNA.

Raw data from automated sequencers and manual sequencing efforts are edited to remove low quality sequences at the end of the sequence run. High quality sequences, usually a result of sequencing templates without excessive salt contamination, generally give about 400 base pairs of reliable sequence data; shorter sequences give fewer bases of reliable data. A 50-base pair polynucleotides is long enough to be translated into about a 16 amino acid peptide sequence. This length is sufficient to observe similarities when they exist in a database search. Also, 50 nucleotides are generally sufficient for unique identification of specific location in genomic DNA of a sequence coding for unique protein. Furthermore, a 50-base pair sequence is long enough to design a PCR primer from the sequence to amplify the complete polynucleotides.

668240" 20570660

The polynucleotides of the present invention are highly specific markers or probes for the corresponding complete gene coding regions and complete genes conferring neural plasticity. The polynucleotides of the present invention are partial sequences, in other words, they represent a relatively small coding region or untranslated region of the genes. However, the disclosed polynucleotides will hybridize, under sufficiently stringent conditions, only with that gene to which they correspond in any species, i.e., feline and human. Suitably stringent hybridization conditions include, for example, a sequence identity of at least about 80% base pair identity and, preferably, at least 90% base pair identity. This property permits the use of the polynucleotides of the present invention to isolate the entire coding region and even the entire sequence using any one of several suitable techniques, including 5'-RACE Polymerase Chain Reaction, described in detail in Innis et al., *PCR Protocols: A Guide to Methods and Applications*, Academic Press, Inc., 1990, incorporated herein by reference. Therefore, only routine laboratory work is necessary to parlay the unique sequence into the corresponding unique complete gene sequence.

The first step in determining where a polynucleotide is located in the genomic region is to analyze the sequence for the presence of a coding sequence. This can be accomplished using any one of several suitable means, including the CRM program, which predicts the extent and orientation of the coding region of a sequence or the ESEE program Cabot and Beckenbach, "Simultaneous editing of multiple nucleic acids and protein sequences with ESEE," *Comput. Applic. Biosci.* 5:233-234, 1989, incorporated herein by reference. Based on this information, one can infer the presence of start or stop codons within a sequence and whether the sequence is coding or not. If stop or start codons are present, then the polynucleotide can cover both parts of the 5'-

untranslated or the 3'-untranslated part of the mRNA as well as part of the coding sequence. If no coding sequence is present, it is likely that the differentially expressed molecule is derived from the 3'-untranslated sequence due to its longer length and the fact that most cDNA library construction methods are biased with the 3' end of the mRNA. Based on this information, complete sequences can be obtained from polynucleotides of the present invention by any suitable means known in the art, including 5'-RACE polymerase chain reaction and cDNA screening. The polynucleotides of the present invention are specific tags for a messenger RNA molecule. The complete sequence of that messenger RNA, in the form of cDNA, can be determined using the polynucleotide as a probe to identify a cDNA clone corresponding to a full-length transcript followed by sequencing of that clone. The polynucleotide or the full-length cDNA clone can also be used as a probe to identify a genomic clone or clones that contain the complete gene including regulatory and promoter regions, exons, and introns.

Polynucleotides of the present invention can be used as probes to identify the full length cDNA clones from which they were derived or to screen other cDNA libraries. Corresponding cDNA clones display at least a 90% homology, typically a 95% homology, and preferably a 97% homology to the coding region of the polynucleotides of the present invention.

One of ordinary skill in the art will appreciate that the probes may be made and used employing any one of several techniques, including, for example, nick translating and random primer labeling with ^{32}P using DNA polymerases, described in detail in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1989, incorporated herein by reference. A lambda library can then be directly screened with the labeled sequences of interest or the library can be converted en masse to pBluescript (Stratagene, La Jolla,

CA) to facilitate bacterial colony screening using methods known in the art. Briefly, filters with bacterial colonies containing the library of pBluescript or bacterial lines containing lambda plaques are denatured and the DNA is fixed to the filters. The filters are hybridized with the labeled probe, using hybridization conditions described by Davis et al., *Basic Methods in Molecular Biology*, Elsevier Press, NY, 1986, incorporated herein by reference. The polynucleotides of the present invention, cloned into lambda or pBluescript, can be used as positive controls to assess background findings and to adjust the hybridization and washing stringencies necessary for accurate clone identification. The resulting autoradiograms are compared to duplicate plates of colonies or plaques; each exposed spot corresponds to positive colony or plaque. The colonies or plaques are selected, expanded, and the DNA is isolated from the colonies for further analysis and sequencing.

Positive cDNA clones in phage lambda are analyzed to determine the amount of additional sequence they contain using PCR with one primer from the polynucleotides of the present invention and the other primer from the vector. Clones with a larger insert PCR product than the original differentially expressed molecule clone are analyzed by restriction digestion and DNA sequencing to determine whether they contain an insert of the same size or similar size as the mRNA on a Northern blot.

Once one or more overlapping cDNA clones are identified, the complete sequence of the clones can be determined. The preferred method is to use exonuclease III digestion, McCombie et al., *Methods* 3:33-40, 1991, incorporated herein by reference. Briefly, a series of deletion clones is generated, each of which is sequenced. The resulting overlapping sequences are assembled into a single contiguous sequence of high redundancy (usually 3-5

663240 20570660

overlapping sequences at each nucleotide position), resulting in a highly accurate final sequence.

A similar screening and clone selection approach can be applied to obtaining cosmid or lambda clones from a genomic DNA library that contains the complete gene from which the polynucleotide was derived (Kirkness et al., *Genomics* 10:985-995, 1991). Although the process is much more laborious, these genomic clones can be sequenced in their entirety also. A shotgun approach is preferred to sequencing clones with inserts longer than 10 kb (genomic cosmid and lambda clones). In shotgun sequencing, the clone is randomly broken into many small pieces, each of which is partially sequenced. The sequence fragments are then aligned to produce the final contiguous sequence with high redundancy. An intermediate approach is to sequence just the promoter region and the intron-exon boundaries and to estimate the size of the introns by restriction endonuclease digestion.

Using the sequence information provided herein, the polynucleotides of the present invention can be derived from natural sources or synthesized using known methods. Sequences falling within the scope of the present invention are not limited to the specific sequences described, but include the corresponding human sequences, complementary sequences, allelic and species variations thereof, and portions thereof of at least 15 to 18 base pairs. (Sequences of at least 15 to 18 bases can be used, for example, as PCR primers or as DNA probes.) Preferably, sequences are at least 50 base pairs in length.

In addition, the invention includes the entire coding sequence associated with the specific polynucleotides of bases described in the sequence listing, as well as portions of the entire coding sequence of at least 15-18 bases and allelic and species variations thereof. Furthermore, to accommodate codon variability, the invention includes sequences coding for the same amino

0030507 042299

acid sequences as do the specific sequences disclosed herein. Finally, although the error rate in the manual and automated sequencing techniques used in the present invention is small, there remains some chance of error.

- 5 Therefore, claims to particular sequences should not be so narrowly construed as to require inclusion of erroneously identified bases or exclude corrections.

Any specific sequence disclosed herein can be readily screened for errors by resequencing in both
10 directions (i.e., sequence both strands of cDNA).

In another aspect of the invention, the invention relates to those sequences of SEQ. ID. NOS.: 93-120 that comprise the cDNA coding sequence for known polypeptides as depicted in Table I.

15

Table I

Seq. ID No.	Clone No.	Putative Identification	Species	Accession	SCORE	% ID	Length (nt/aa)
120	pKVC4	alpha internexin	Rat	RNINTLAA	251	72	169 nt
119	pKVC6	TAPA-1	Human	HSTAPA1	745	87	244 nt
118	pKVC6B	Amphiphysin	Chicken	GDAMPHIP	113	47	38 aa
117	pKVC9	v-fos transformation effector	Human	HSFTE1A	975	93	277 nt
116	pKVC10	Cytoskeletal gamma actin	Human	HSACTCGR	245	84	88 nt
115	pKVC12	90 kD heat shock protein	Human	HSHSP90R	320	76	161 nt
114	pKVC17	Substance P receptor	Rat	RNSPRO5	214	96	57 nt
113	pKVC18	Cytochrome oxidase I	Human	MIHSCG	686	80	266 nt
112	pKVC21	nrc-1b	Xenopus	XLNRP	129	57	200 nt
110	pKVC22	clq beta isoform	Human	HSC1QBR	221	94	47 aa
109	pKVC27	Cytoplasmic Succinyl CoA synthetase	Rat	RNGLTA	820	86	272 nt
108	pKVC35	Vacuolar proton ATPase channel	Human	HSPCHSUC A	575	80	250 nt
107	pKVC46	71kD heat shock cognate protein	Human	HSHSC70	582	83	240 nt
105	pKVC49	Contactin	Chicken	GGCONTAC	330	69	223 nt
104	pKVC55	LAMP-1	Human	HSLAMP1A	619	77	293 nt
102	pKVC79	Nuclear encoded ADP/ATP transporter	Bovine	BTADTPMT	377	98	74 aa
101	pKVC80	VAMP-2	Rat	RNVAMPB	461	76	253 nt

100	pKVC82	Carboxypeptidase Z	Human	HSCARBE	558	83	203 nt
99	pKVC86	Ribosomal protein S27	Rat	RRS27	300	76	132 nt
98	pKVC90	hnRNP core protein A1	Human	HSRNPA1	880	94	248 nt
97	pKVC91	NADH dehydrogenase	Bovine	MIBTXX	206	79	51 aa
96	pKVC92	Mitochondrial hinge protein	Human	HSHINGE	214	64	135 nt
95	pKVC105	mRNA for prolif. associated protein	Human	HSPAG	98	77	48 aa
94	pKVC108	Initiation factor eIF-4A	Mouse	MMEIF4AL	445	75	254nt
93	pKVC134	alpha tubulin	Human	HSHA44G	312	100	60 aa

These sequences have greater than 90% identity with known amino acid sequences.

Another aspect of the present invention relates to those polynucleotides encoded by sequences designated as one of SEQ. ID. NOS.: 1-92 and 121-132. These sequences encode polypeptides having little or no similarity to known amino acid sequences. These polynucleotides can be parlayed into their associated polypeptides using any one of a variety of techniques, including, for example, synthesizing the polypeptide encoded by the polynucleotide using commercially available peptide synthesizers including the Applied Biosystems Peptide Synthesizer (Perkin-Elmer). This is particularly useful in producing small peptide end fragments of larger polypeptides. Generally, the term "associated polypeptides" includes polypeptide demonstrating an identity of greater than 80%, typically greater than 90%, and preferably greater than 92% to the polynucleotides of the present invention.

Alternatively, the associated polypeptides may be produced by inserting the polynucleotides into a host organism capable of expressing the polynucleotide. Suitable organisms include bacteria, yeast, a cell line, or a multicellular plant or animal. The literature is replete with examples of suitable host organisms and

00301507 "042399
668240" ZNSTOE60

expression techniques. For example, naked polynucleotide (DNA or mRNA) can be injected directly into muscle tissue of animals where it is then expressed. Alternatively, the coding sequence, together with appropriate regulatory regions (i.e., a construct) can be inserted into a vector, which is then used to transfect or infect a cell. The cell, which may or may not be part of a larger organism, then expresses the polypeptide.

Recombinant binding partners of the present invention include proteins (e.g., antibodies), peptides and small organic molecules. Antibodies generated against the polypeptide corresponding to a sequence of the present invention can be obtained by direct injection of the naked polynucleotide into an animal or by administration of the polypeptide to an animal, preferably a non-human, using methods known in the art. The antibody so obtained will then bind the polypeptide itself. In this manner, even a sequence encoding only a fragment of the polypeptide can be used to generate antibodies binding the whole native polypeptide. Such antibodies can then be used to isolate the polypeptide from tissues expressing that polypeptide. Moreover, a panel of such antibodies specific to a large number of polypeptides, can be used to identify and differentiate such tissue.

Despite the potential utility of antibodies as recombinant binding partners, there may be pharmaceutical applications for which they are not appropriate due to their cost, potential for immunogenicity, or need for specialized forms of delivery such as orthotopic or oral administration. For these purposes, small organic compounds or peptides may also be developed. Such peptides and compounds may be developed through: (1) screening of bacterial peptide expression libraries, antibody paratope analogs or antibody Fab expression libraries to identify peptide or antibody variable region inhibitors (*Gene* 73:305, 1988; *Proc. Nat. Acad. Sci. USA* 87:6378, 1990; *BioChromatography* 5:22, 1990; *Protein*

00301507 042899
668240 20510360

Engineering 3:641, 1989); (2) rational drug design programs using antibodies as a "pharmacophore" to create organic molecule analogs (*Biotechnology*, Jan. 19, 1991), or traditional rational drug design programs using
 5 crystallized vitamin receptor to identify peptide or organic inhibitors (*Biochem. J.* 268:249, 1990; *Science* 248:1544, 1990); and (3) screening a library of organic molecules.

Other assays can also prove useful, including
 10 specific binding assays using antibodies which act as competitive antagonists. Through these means a repertoire of protein and non-protein molecules suitable for human use can be generated, and may be used to define optimal regimens for antagonizing or upregulating the activity of
 15 polypeptides encoded by the polynucleotides.

The amount of recombinant binding partners and timing of administration is determined by *in vitro* study followed by *in vivo* experimentation.

Another aspect of the present invention includes
 20 constructs including one or more of the polynucleotides, as broadly described above. The constructs comprise a vector, such as a plasmid or viral vector, into which a polynucleotide of the present invention has been inserted, in either a sense or antisense orientation. Preferably,
 25 the construct further contains regulatory regions, including, for example, a promoter, operably linked to the polynucleotide. Large numbers of suitable vectors and promoters are known and are commercially available. The following vector constructs are provided by way of
 30 example:

Bacterial: pBs, phase script 0X174, pBluescript SK, pBsKs, pNH8a, pNH16a, pNH18a, pNH46a (Stratagene), ptrc99A, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia).

Eukaryotic: pWLneo, pSV2cat, pOG44, pXT1, pSG
 35 (Stratagene), pSVK3, pBPV, pMSG, pSVL(Pharmacia).

668240" 20570660

Viral: HSV-1, retroviral, adenoviral and vaccinia virus. See, for example, U.S. Patent Application Serial No. 08/213,799 incorporated herein by reference.

Promoter regions can be selected from any
5 desired gene using chloramphenicol transferase ("CAT")
vectors or other vectors with selectable markers. Two
appropriate vectors are pKK232-8 and pCM7. Particular
named bacterial promoters include lacI, lacZ, T3, T7, gpt,
lambda P_{RO} and trc. Eukaryotic promoters include CMV
10 immediate early, HSV thymidine kinase, early and late
SV40, LTRs from retrovirus and mouse metallothionein-I.
Selection of the appropriate vector and promoter is well
within the level of ordinary skill in the art.

In a further embodiment, the present invention
15 relates to host cells containing the above-described
construct. The host cell can be a higher eukaryotic cell,
such as a mammalian cell; or a lower eukaryotic cell, such
as a yeast cell; a prokaryotic cell, such as a bacterial
cell. Introduction of the construct into the host cell
20 can be affected using any one of several methods known in
the art, including by calcium phosphate transfection, DEAE
dextran mediated transfection, infection, or
electroporation, as described in detail in Davis et al.,
Basic Methods of Molecular Biology, 1986, incorporated
25 herein by reference.

The constructs in host cells can be used in a
conventional manner to produce the gene product coded by
the recombinant sequences as described above, or the host
cells can be administered directly to an animal in need
30 thereof as described below. Alternatively, the encoded
polypeptide can be synthetically produced by conventional
peptide synthesizers.

The polynucleotides of the present invention
generally possess the capability of encoding polypeptides
35 associated with energy metabolism and mitochondrial
function. These peptides are associated with the special
needs of the critical period which requires high levels of

668240 20510660

energy to be expended within the CNS. The polynucleotides of the present invention play an important role in providing the necessary elevated function and increased energy metabolism associated with this process.

5 The polynucleotides of the present invention generally possess the capability of encoding polypeptides associated with cell membrane associated proteins. Cell membrane associated proteins may be neurotransmitter receptors. As such, they may increase the sensitivity of
10 neurons to various neurotransmitters and hormones. This results in the activation of intercellular cascades, increasing neural plasticity.

 The polynucleotides of the present invention generally possess the capability of encoding polypeptides
15 associated with neurotransmitter release and processing associated proteins. Thus, the polynucleotides of the present invention administered to a warm-blooded animal would increase neurotransmitter releases, altering the strength of connections between the cells. The change in
20 neurotransmitter release and increase synthesis of neurotransmitter represents a prime example of increased neural plasticity.

 The polynucleotides of the present invention generally possess the capability of encoding polypeptides
25 associated with cell or tissue remodeling associated proteins. These proteins include heat shock proteins which are known to play a role in protecting cells in the body from various stressers. Up-regulation of the function of this protein would assist in neural
30 protection.

 The polynucleotides of the present invention generally possess the capability of encoding polypeptides associated with cytoskeletal proteins. These polypeptides control rigidity and direction of the growth of neurons
35 during their regenerative and plastic phases. The cytoskeletal proteins associated with the polynucleotides of the present invention play a role in directing cell and

09303507 043899
668240 20570660

fiber growth during the recovery of function after neural injury. The polynucleotides of the present invention generally possess the capability of encoding polypeptides associated with mRNA transcription and processing. Thus, 5 these sequences play a role in facilitating the differentials transcription of the described sequences.

The polynucleotides and complete gene sequences of the present invention are also valuable for chromosome identification. Each sequence is specifically targeted 10 to, and can hybridize with, a particular location on an individual chromosome. Moreover, there is a current need for identifying particular sites on the chromosome. The present invention constitutes an expansion of the available chromosome markers. Using any one of several 15 techniques, the polynucleotides and the corresponding complete sequences can similarly be mapped to chromosomes. The mapping of the polynucleotides to chromosomes according to the present invention is an important first step in correlating those sequences with genes associated 20 with genetic disorders.

Briefly, within one embodiment, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 base pairs) from the polynucleotides of the present invention. Computer analysis of the polynucleotide is 25 used to rapidly select the primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids 30 containing the human gene corresponding to the polynucleotides of the present invention will yield an amplified fragment.

PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular differentially 35 expressed molecule to a particular chromosome. Three or more clones can be assigned per day using a single thermal cycler. Using the present invention with the same

04339 04339 04339

oligonucleotide primers, sublocalization can be achieved with panels of fragments from specific chromosomes or pools of large genomic clones in analogous manner. Other mapping strategies that can similarly be used to map a polynucleotide to its chromosome include *in situ* hybridization, prescreening with labeled flow sorted chromosomes and preselection by hybridization to construct chromosome specific cDNA libraries.

Fluorescence *in situ* hybridization (FISH) of a cDNA clone to a metaphase chromosomal spread can be used to provide a precise chromosomal location. This technique can be used with cDNA as short as 500 or 600 bases; however, clones larger than 2000 base pairs have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. FISH requires the use of the clone from which the polynucleotide was derived, and the longer the better. Two thousand base pairs is good, 4,000 base pairs is better, and more than 4,000 is probably not necessary to get results in a reasonable percentage of the time. For a review of this technique, see Verma et al., *Human Chromosomes: A Manual of Basic Techniques*, Pergamon Press, New York, 1988, incorporated herein by reference.

Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome or as panels of reagents, for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross-hybridization during chromosomal mapping.

Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. The relationship between genes and diseases that have been mapped to the same chromosomal region are

then identified through linkage analysis, coinheritance of physically adjacent genes. See, for example, V. McKusick, *Mendelian Inheritance in Man*, available on line through Johns Hopkins University Welch Medical Library, 5 incorporated herein by reference.

Next, it is necessary to determine the differences in the cDNA or genomic sequence between affected and unaffected individuals. If a mutation is observed in some or all of the affected individuals but 10 not in any normal individuals, then the mutation is likely to be causative agent of the disease.

With current resolution of physical mapping and genetic mapping techniques, a cDNA precisely localized to a chromosomal region associated with the disease could be 15 one of between 50 and 500 potential causative genes. This assumes one megabase mapping resolution and one gene per 200 kilobases.

Comparison of affected and unaffected individuals generally involves first observing structural 20 alterations in the chromosomes, such as deletions or translocations that are visible from chromosomal spreads or detectable using PCR based on that cDNA sequence. Ultimately, complete sequencing of genes from several individuals is required to confirm the presence of a 25 mutation and to distinguish mutations from polymorphisms.

In addition to the foregoing, the sequences of the invention, as broadly described, can be used to control gene expression through triple helix formation or antisense DNA or RNA, both of which methods are based on 30 binding of a polynucleotide to DNA or RNA. Polynucleotides suitable for use in these methods are usually 20 to 40 bases in length and are designed to be complementary to a region of the gene involved in transcription (triple helix; see Lee et al., *Nucl. Acids* 35 *Res.* 6:3073, 1979; Cooney et al., *Science* 241:456, 1988; and Dervan et al., *Science* 251:1360, 1991) or to mRNA itself (Antisense-Okano, *J. Neurochem.* 56:560, 1991;

668240 2057060

Oligodeoxynucleotides as Antisense Inhibitors of gene Expression, CRC Press, Boca Raton, FL, 1988). Triple helix formation optimally results in a shutoff of RNA transcription from DNA, while antisense RNA hybridization
5 blocks translation of an mRNA molecule into polypeptide. Information contained in the sequences of the present invention is necessary and sufficient for the design of an antisense or triple helix oligonucleotide.

The polynucleotides of the present invention are
10 useful tools for the treatment of degenerative disorders, for assisting neural cell repair and regrowth, the treatment of learning disorders, and for enhanced memory and learning capacity using gene therapy.

Those polynucleotide sequences that are
15 associated with neural plasticity may be empirically tested in vivo, by formulating the antisense construct or the triple helix construct of a polynucleotide of the present invention and inserting the sequence into the visual cortex of a critical stage kitten using any means
20 described above. Those sequences which are capable of blocking neural plasticity in critical stage kittens will be therapeutically effective. The result can be subsequently assayed using any one of a variety of techniques, including electrophysiological methods
25 described in Kandel et al., *Principles of Neural Science*, 3d ed., Elsevier Press, NY, 1991, incorporated herein by reference, and, alternatively, by anatomical measures of lateral geniculate cell size, which would normally show shrinkage of cells associated with visual deprivation.
30 Those areas in which the constructs have been effused used would exhibit no shrinkage.

In one aspect of the invention the polynucleotides of the present invention are administered to treat degenerative disorders. In the context of the
35 present invention, the term "degenerative," as applied to disorders of the nervous system, is used to designate a group of disorders in which there is a gradual, generally

668240 20570660

symmetric, relentlessly progressive wasting away of neurons. The term "degenerative diseases of the nervous system" is intended to include any of the diseases referred to in Table II, as well as other brain
 5 disturbances including, but not limited to, depression, dementia, and schizophrenia. This term is used interchangeably with the terms "diseases with a neurological dysfunction or disorder" or "neurodegenerative diseases," which are intended to have
 10 the same meaning.

Since etiological classification of such disorders is virtually impossible, subdivision of degenerative diseases into individual syndromes rests on descriptive criteria, based largely on pathologic anatomy
 15 but to some extent on clinical aspects as well. Table II groups the disease states according to the outstanding clinical features that may be found in an actual case.

Table II

CLINICAL CLASSIFICATION OF THE DEGENERATIVE DISEASES OF THE NERVOUS SYSTEM

- I. Syndrome in which progressive dementia is
 25 an outstanding feature in the absence of other prominent neurologic signs
 - A. Diffuse cerebral atrophy
 1. Senile dementia
 2. Alzheimer's disease
 - 30 B. Circumscribed cerebral atrophy (Pick's disease)
- II. Syndrome in which progressive dementia is combined with other neurologic signs
 - A. Principally in adults
 - 35 1. Huntington's chorea
 2. Cerebrocerebellar degeneration
 - B. In children and adults
 1. Amaurotic family idiocy (neuronal lipidoses)

663240 20570660

- 668240" 40570560
- 2. Leukodystrophy
 - 3. Familial myoclonus epilepsy
 - 4. Hallervorden-Spatz disease
 - 5. Wilson's disease
(hepatolenticular degeneration,
Westphal-Strumpell
pseudosclerosis)
- III. Syndrome chiefly manifested by gradual
development of abnormalities of posture or
involuntary movements
- A. Paralysis agitans
 - B. Dystonia musculorum deformans (torsion
dystonia)
 - C. Hallervorden-Spatz disease and other
restricted dyskinesias
 - D. Familial tremor
 - E. Spasmodic torticollis
- IV. Syndrome chiefly manifested by slowly
developing ataxia
- A. Cerebellar degenerations
 - B. Spinocerebellar degenerations
(Friedrich's ataxia, Marie's
hereditary ataxia)
- V. Syndrome with slowly developing muscular
weakness and wasting
- A. Without sensory changes; motor system
disease
 - 1. In adults
 - a. Amyotrophic lateral
sclerosis
 - b. Progressive muscular atrophy
 - c. Progressive bulbar palsy
 - d. Primary lateral sclerosis
 - 2. In children or young adults
 - a. Infantile muscular atrophy
(Werdnig-Hoffmann disease)
 - b. Other forms of familial
progressive muscular atrophy
(including Wohlfart-
Kugelberg-Welander syndrome)

- c. Hereditary spastic paraplegia
 - B. With sensory changes
 - 1. Progressive neural muscular atrophy
 - a. Peroneal muscular atrophy (Charcot-Marie-Tooth)
 - b. Hypertrophic interstitial neuropathy (Dejerine-Sottas)
 - 2. Miscellaneous forms of chronic progressive neuropathy
- VI. Syndrome chiefly manifested by progressive visual loss
 - A. Hereditary optic atrophy (Leber's disease)
 - B. Pigmentary degeneration of the retina (retinitis pigmentosa)

In one embodiment of the present invention, the polynucleotides of the present invention are inserted into a construct, as described above, or delivered by other means known in the art and administered to an animal suffering from, or genetically susceptible to, a neurodegenerative disease or diseases of tissue which share a common embryological basis with the nervous system. This results in the amelioration of the primary neurological symptoms of the neurodegenerative disease. Similar improvement in overall functional ability should also be seen.

In another aspect of the present invention, the polynucleotides are administered to assist the recovery of injured neurons. Neurons can be injured as a result of a direct injury or disease. For example, acute injuries to the central nervous system or peripheral nervous tissue can occur from, among others, stroke, brain injury or spinal cord injury. The insertion of the polynucleotides of the present invention confers the ability to direct growing or regenerating axons within the central nervous

668240 00570000

system and peripheral nervous system and enabling them to form synapses with their neighbors.

In another aspect of the present invention, the polynucleotides are used to treat learning disorders. In the context of the present invention, the term "learning disorder" refers to disorders which are characterized by a decreased ability to process and store information. Such learning disorders include dyslexia, dysphoria, aphasia, disgraphia, mental retardation, including Down's Syndrome. Administration, as described in detail below, of the polynucleotides, as broadly described above, results in improvement in overall functional ability.

In another aspect of the present invention, the polynucleotides are used to treat those who do not indicate obvious pathology. Normal individuals so as to enhance memory and learning capacity. In the context of the present invention, the term "enhanced memory and learning capacity" refers to the increased capacity to process and store information. Administration of the polynucleotides, as broadly described above, should result in increased learning capacity.

Using methods known in the art and described in detail below, the polynucleotides are delivered to the particular neuronal tissue in need. At the new location the genes provide neural plasticity; essentially providing the cell with the necessary material to compensate for the degeneration. Preferably, the nucleotides are administered in a construct, however, they may be delivered by any suitable means known in the art.

The constructs can be administered by any means which will ensure that it reaches the desired location. Preferably, the constructs are directed to the portion affected, however, general administration would not have an adverse effect. The specific regions of the brain are reviewed in Mayeux, E. and Kandel, E.R., Chapter 54 (pp. 839-851) in Kandel et al., *Principles of Neural Science*,

668240 20510560

3d ed., Elsevier Press, NY, 1991, incorporated herein by reference.

One of the biggest impediments to delivery of pharmaceuticals to the central nervous system is the blood-brain barrier. In the context of the present invention, the term "blood-brain barrier" refers to the blood-brain barrier made up of brain microvessel endothelial cells characterized by tight intercellular junctions, minimal pinocytic activity, and the absence of fenestra. These characteristics endow these cells with the ability to restrict passage of most small polar blood-borne molecules (e.g., neurotransmitters, including catecholamines and neuropeptides) and macromolecules (e.g., proteins) from the cerebrovascular circulation to the brain. The blood-brain barrier contains highly active enzyme systems as well, which further enhance the already very effective protective function. It is recognized that transport of molecules to the brain is not determined solely by the molecular size but by the permeabilities governed by the specific chemical characteristics of the permeating substance. Thus, besides molecular size and lipidicity, the affinity of the substances to various blood proteins, specific enzymes in the blood, or the blood-brain barrier, will considerably influence the amount of the drug reaching the brain. Several mechanisms for crossing the blood-brain barrier are described below and others are known in the art.

The term "treatment" as used within the context of the present invention, refers to reducing or alleviating symptoms in a subject, preventing symptoms from worsening or progressing, inhibition or elimination of the causative agent, or prevention of the infection or disorder in a subject who is free therefrom. Thus, for example, treatment of infection includes destruction of the infecting agent, inhibition of or interference with its growth or maturation, neutralization of its pathological effects and the like. A disorder is

09301507 04899
668240 20510660

"treated" by partially or wholly remedying the deficiency which causes the deficiency or which makes it more severe. An unbalanced state disorder is "treated" by partially or wholly remedying the imbalance which causes the disorder or which makes it more severe.

There are unique considerations in the treatment of central nervous system dysfunction. Unlike other tissues, brain tissue is not redundant. It is highly differentiated, compartmentalized, and irreplaceable. Thus neuropharmaceutics must be found non-toxic to normal tissues. However, it has been difficult to find the most efficacious route circumventing the blood-brain barrier.

One way to bypass the barrier is by intracerebral spinal fluid administration by lumbar puncture or by the intraventricular route. Catheterization using the aommaya reservoir is used, but logistics dictate that to be a last resort.

Because the barrier is selective, some drugs can be administered orally. Since lipophilic chemicals or agents that mimic the neural amino acids can bypass the barrier by mere diffusion or by transport via the energy-dependent membrane bound character, respectively. Thus constructs can be prepared to add lipid and/or carbohydrate groups to the construct to make it more lipophilic and then hence the ability to cross the blood-brain barrier.

Transient reversible modification of the blood-brain barrier is accomplished in either of two ways -- osmotic opening or metrizol opening. The first method is based on increasing capillary permeability by osmotically induced shrinkage of the endothelial cells which cause the widening of the intercellular-type junctions. The osmotic load is generally a hyperosmotic water-soluble agent such as mannitol or arabinose. Briefly, under general anesthesia, a transfemoral catheter is introduced into the internal carotid or vertebral artery and 150-300 ml infusion of 25% mannitol is

administered at 6-10 mg/sec for thirty seconds. The intravenous infusion of the construct of the present invention is begun approximately 5-7 minutes before the mannitol infusion and is continued for fifteen minutes.

- 5 The transfemoral catheter is removed and the patient observed for 24-48 hours.

Alternatively, the active agent (the construct or polynucleotide) may be linked to the osmotic agent (mannitol, arabinose, glucose or other sugar moiety), and a single infusion may be used. Conventional techniques may be used to link the active agent and the osmotic agent. The linked agent itself will then cause the osmotically induced shrinkage of the endothelial cells in order to widen the tight intracellular junctions. The linked agent may be designed such that the active agent is cleared from the linked agent after the blood-brain barrier has been crossed.

In the second method, capillary permeability is increased by eliciting seizure activity using a central nervous system stimulant such as pentylenetetrazol. This technique is similar to that of osmotic opening with replacement of mannitol infusion by parenteral delivery of the stimulant.

A further alternative method of delivering polynucleotides to target areas of the brain is transport the polynucleotide into the brain by means of defective herpes simplex virus I (HSV I) vector using a method described by Geller et al., Science 241:1667, 1988. Particularly the defective HSV I vector described by Geller et al., *supra*, is pHSVlac, which contains the *E. coli* LacZ gene under the control of the HSV immediate early 4/5 promoter.

In order to use this HSV I vector in the present invention, the polynucleotide sequence is inserted into the defective HSV I vector using conventional technique. This new vector containing the polynucleotide sequence can then enter the brain.

09304507-042899
668240-20570560

668240-20970660

The preferred method of administration is microinjection of the polynucleotide, alone or in a pharmaceutically suitable carrier or diluent, through a stereotactically-located pipette or syringe. Suitable
5 locations vary with application, but include intraocular and brain injections.

Pharmaceutical compositions containing the constructs in an admixture with a pharmaceutical carrier or diluent can be prepared according to conventional
10 pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., intravenous, oral topical, aerosol, suppository, parenteral or spinal injection.

15 In preparing the compositions in oral dosage form, any of the usual pharmaceutical medium can be employed such as, for example, water, glyucose, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like.

20 In the case of oral liquid preparations (such as, for example, suspensions, elixirs and solutions); or carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like.

25 In the case of oral solid preparations, for example, powders, capsules, and tablets. Because of their ease in administration, tablets and capsules present the most advantageous oral dosage unit form, in which solid pharmaceutical carriers are obviously employed. If
30 desired, tablets may be sugar-coated or enteric-coated by standard techniques.

In the case of parenterals, the carrier will usually comprise sterile water, though their ingredients, for example, to aid solubility or for preservative
35 purposes may be included. Injectable suspensions may also be prepared in which case appropriate liquid carriers such

as suspending agents, pH adjusting agents, isotonicity adjusting agents and the like may be employed.

In the case of topical administration, the carrier may take a wide variety of forms, depending on the form of the preparation, such as creams, dressings, gels, lotions, ointments, or liquids.

Aerosols are prepared by dissolving or suspending the active ingredient in a propellant such as ethyl alcohol or in a propellant and solvent phase. Suppositories are prepared by mixing the active ingredient with a lipid vehicle such as theobroma oil, cacao butter, glycerin, gelatin, or polyoxyethylene glycols.

If necessary, the pharmaceutical preparations can be subjected to conventional pharmaceutical adjuvants such as preserving agents, stabilizing agents, wetting agents, salts for varying the osmotic pressure, and the like. The present pharmaceutical preparations may also contain other therapeutically valuable substances.

In another aspect of the present invention, constructs, including polynucleotides, may be delivered by chronic infusion using any suitable method known in the art, including an osmotic minipump (Alza Corp.) or delivery through a time release or sustained release medium. Suitable time release or sustained release systems include any methods known in the art, including media such as Elvax (or see, for example, U.S. Patent Nos. 5,015,479, 4,088,798, 4,178,361, and 4,145,408). When using chronic infusion, time release, or sustained release mechanisms, the construct composition may be injected into the cerebrospinal fluid via intrathecal or intraventricular injections, as well as into the brain substances and intraocular locations.

When the gene is transfected or infected into a mammalian host cell, the mammalian cells may be administered to the patient in need thereof by any method known in the art, including that outlined in U.S. Patent No. 5,082,670 and incorporated herein by reference.

5 The polynucleotide should be administered in a therapeutically effective amount. A therapeutically effective amount is that amount sufficient to treat the disorder. A therapeutically effective amount can be determined by *in vitro* experiment followed by *in vivo* studies. Expression of the inserted polynucleotide can be determined *in vitro* using any one of the techniques described above. Expression of the inserted polynucleotide can be determined *in vivo* using any one of several methods known in the art, including immunofluorescence using a fluoresceinated ligand.

10 The optimal dosage is that which produces maximal improvement with tolerated side effects. It is worth emphasizing that optimal dosage is determined empirically and balances the benefits and adverse side effects.

15 In another aspect of the present invention, the polynucleotides described above are incorporated into a pharmaceutical composition. A pharmaceutical composition contains a therapeutically effective dose of the construct in a suitable pharmaceutical carrier or diluent. Suitable pharmaceutical carriers and diluents are outlined above. A therapeutically effective dose may be determined by *in vitro* experiment followed by *in vivo* studies. The composition may be administered by any one of the methods described above.

20 The following examples are provided by way of illustration, and not by way of limitation. Unless otherwise indicated, the specific protocols used in the following examples are described in detail in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1989.

EXAMPLESExample I:

Two 30-day-old kittens and two adult felines
 5 were deeply anesthetized with 150 mg/kg sodium
 pentobarbital (EUTHANYL, Maple Leaf Foods, Inc.) and
 perfused through the aorta with 1 l of 0.05%
 diethylpyrocarbonate (DEPC) treated PBS buffer for one
 minute. Visual cortices, identifiable by observation,
 10 were carefully dissected out and quickly frozen either in
 liquid nitrogen or in a dry ice/isopentane bath for 5
 minutes. The dissected tissues were stored at -80°C until
 RNA was to be isolated.

15 Example II: Isolation of RNA

a) Total RNA for Northern blot hybridization was
 isolated using the single step method of RNA isolation by
 acid guanidium thiocyanate-phenol-chloroform extraction
 method of Chomczynski and Sacchi. Described in detail in
 20 Chomczynski and Sacchi, "Single step method of RNA
 isolation by acid guanidium thiocyanate-phenol-chloroform
 extraction," *Anal. Biochem.* 162:156-159, 1987,
 incorporated herein by reference.

b) Poly(A) RNA was isolated directly from the tissue of
 25 interest using a FAST TRACK mRNA isolation kit (Invitrogen
 Corporation) or QUICK mRNA PREP (Pharmacia).

Example III: Construction of the cDNA Library

An adult visual cortex plasmid library in
 30 pcDNAII (Invitrogen Corporation) was constructed by a
 modified Gubler-Hoffman procedure, described in detail in
 Gubler and Hoffman, "A simple and very efficient method
 for generating cDNA libraries," *Gene* 25:263-269, 1983,
 incorporated herein by reference. Briefly, the procedure
 35 utilizes the synthesis of first strand cDNA using AMV
 reverse transcriptase (Life Sciences), cleavage of mRNA
 hybrid using *E. coli* RNase H(BRL), and synthesis of second

strand cDNA using *E. coli* DNA polymerase I. Any nicks in the double-stranded cDNA were repaired using *E. coli* DNA ligase (BRL). The double-stranded cDNA was blunt ended using T4 polymerase (BRL). BstXI non-palindromic linkers
 5 (Invitrogen Corporation) were ligated to the double-stranded, blunt-ended cDNA. Following the removal of small length cDNAs and excess linkers using size select 400 columns (Stratagene) the cDNA was ligated to the BstXI cut pcDNA II vector and transformed in DH5 α MAX Efficiency
 10 competent cells (BRL).

Example IV: Preparation of a Kitten
Visual Cortex Specific Probe

In order to obtain the cDNA clones representing
 15 the mRNA enriched in the 30-day-old kitten visual cortex relative to the adult visual cortex, a 30-day-old kitten visual cortex cDNA probe was prepared. The strategy used in the synthesis of the subtractive probe is outlined in Figure 1, and described in detail in Sieve and St. John,
 20 "A simple subtractive hybridization technique employing photoactivatable biotin and phenol extraction," *Nucl. Acids Res.* 16:10937, 1988, incorporated herein by reference.

25 a) Biotinylation of adult mRNA

Twenty μ g of the adult visual cortex poly(A) RNA in 30 μ l sterile diethylpyrocarbonate treated water (DEPC water) was combined with an equal volume of photobiotin acetate (1 mg/ml) in a 1.5 ml screw cap tube in the
 30 darkroom. The tube with its cap closed was placed in ice slurry exactly 10 cm below a 300W reflector lamp for 30 minutes. The mixture was then diluted to 200 μ l with 0.1 M Tris, pH 9, followed by extractions with equal volumes of water saturated 2-butanol until the butanol
 35 layer appeared clear. The biotinylated adult visual cortex mRNA was then ethanol precipitated, washed with 80% ethanol and dissolved in 30 μ l of sterile RNase free

water. The photobiotinylation procedure was repeated to achieve a more efficient biotinylation.

b) Synthesis of Labeled cDNA:

5 A [³²P]-labeled cDNA probe was synthesized from 1 µg of poly(A) RNA derived from the 30-day-old kitten visual cortex using oligo(dt) as a primer and 250 µCi of [α-³²P] dCTP (3000 Ci/mmol; 1Ci=37GBq). This resulted in the antisense cDNA population for the kitten visual cortex
10 with a total incorporation of 10⁸ cpm. The mRNA template was removed by hydrolysis with 0.5 M NaOH at 55°C for 15 minutes. The labeled cDNA (approximately 500 ng) was precipitated with ethanol and used immediately in the subtraction step with the biotinylated adult visual cortex
15 mRNA.

c) Subtractive Hybridization:

In a screw cap vial, the 30 µl of biotinylated adult visual cortex mRNA (10 µg) was mixed with the [³²P]-
20 labeled 30-day-old kitten visual cortex antisense cDNA (0.5 µg) and ethanol precipitated. The final pellet was resuspended in 10 µl of sterile water and 10 µl of 2X hybridization buffer (0.65 M NaCl, 0.04 M Na₂PO₄, pH 6.8, 1 mM EDTA and 0.05% SDS) was added. This mixture was
25 boiled for 1 minute and then incubated at 65°C for 48 hr. Under these conditions, Cot values greater than 1000 were obtained. To the hybridization mixture 30 µl of 10 mM Hepes/EDTA buffer was added followed by the addition of 10 µl of 1 mg/ml of streptavidin. This mixture was mixed
30 and incubated at room temperature for 10 minutes and then extracted with 60 µl of phenol/chloroform. The organic phase was back extracted with 50 µl of Hepes/EDTA buffer and aqueous layers were combined. Another 10 µl of streptavidin was added to the aqueous phase and the
35 mixture was incubated at room temperature for 5 minutes. This mixture was again extracted with an equal volume of phenol/chloroform and precipitated with ethanol. The

final pellet was resuspended in sterile RNase free water and hybridized with a second aliquot of biotinylated adult visual cortex mRNA (10 µg) as described above. The labeled single stranded cDNA remaining after two rounds of subtraction represented 3%-10% of the starting material.

Example V: Screening of cDNA library

Approximately 12,000 independent cDNA clones derived from a 30-day-old visual cortex cDNA library were plated on ampicillin plates at a density of 1,000 clones/plate. The colonies were allowed to grow to about 0.5 mm in diameter and a sterile nylon membrane was carefully placed on each plate with proper identifiable orientation. The plates were incubated for 2 additional hours. The filters were prehybridized in 2X SCC, 1% SDS, 0.5% nonfat dry milk, pH 7.0 for 1 hour at 65°C. The filters were then removed and hybridized with the subtractive probe (200,000 cpm/ml) in a solution containing 6X SSC, 1% SDS, 0.5% nonfat dry milk, pH 7.0 at 65°C for 16 hours. The post hybridization washes were done at 50°C in 0.1X SSC, 1% SDS, pH 7.0. The filters were then exposed to Kodak XAR 5 film for 6 hours. The positive clones were picked up and stored in 96 well microtiter plates containing 200 µl of 20% glycerol in Luria broth medium.

Example VI: Synthesis of RNA probes

The plasmid DNA was isolated by the alkaline lysis miniprep method. The plasmid DNA was linearized by digestion with either XhoI or HindIII. Depending upon the orientation of the cDNA inserts, the corresponding antisense riboprobes were prepared using either the SP6 RNA polymerase or the T7 RNA polymerase with [³²P]CTP following the instructions in the PROMEGA kit (Promega Corp.).

Example VII: Northern Blot Hybridization

10 µg of various total RNAs (determined by A₂₆₀ spectrophotometric measurements) were electrophoresed on a 1.1% agarose gel containing 0.66 M formaldehyde at 4V/cm for 4 to 4.5 hours. RNA from the gel was transferred to a nylon based membrane (Gene Screen, NEN) using the procedure described by Thomas, "Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose," *Proc. Natl. Acad. Sci. USA* 77:5201-5205, 1980, incorporated herein by reference. After transfer of the RNA to nylon membranes, the membrane was exposed to a UV transilluminator for 1 min. Khandjian, "UV crosslinking of RNA to nylon membranes enhances hybridization signals," *Molec. Biol. Rep.* 11:107-115, 1986, incorporated herein by reference. The filters were baked at 80°C for 1-2 hr. Prehybridization was carried out for 30 min. in 50% deionized formamide, 0.25M sodium phosphate, pH 7.2, 0.25M NaCl, 1mM EDTA, 7% SDS and 5% polyethanol glycol (MW 8000). Hybridization was performed in the same buffer with the inclusion of 1X 10⁶ cpm/ml. of the individual riboprobes. Four 20 min. post hybridization washes were carried out in 0.04M sodium phosphate, pH 7.2, 1% SDS, 1mM EDTA at 65°C. The membranes were then rinsed three times in 2X SSC for 5 min. at room temperature followed by 15 min. treatment with 2X SSC containing 1 µg/ml of RNase A. The filters were rinsed for 30 min. at 50°C in 0.1X SSC, 0.1% SDS and then exposed to Kodak XAR5 films for 1-3 days, depending on the desired intensity, in the presence of an intensifying screen.

Example VIII: DNA Sequence Analysis

The plasmid DNA was isolated by the alkaline lysis miniprep method. Approximately 5 µg supercoiled plasmids were further purified by passing them through Plasmid-Quick columns (Stratagene, Corp.) and then subjected to the dideoxy sequencing. Sanger et al., "DNA

sequencing with chain-terminating inhibitors," *Proc. Natl. Acad. Sci. USA* 74:5463-5467, 1977, incorporated herein by reference. Each purified template was sequenced at least twice either manually using a SEQUENASE Version 2.0 kit
 5 (USB) or using a model number 373A ABI automated DNA sequencer. The sequencing reactions for the automated ABI DNA sequencer were performed using a PERKIN-ELMER thermal cycler with the annealing of dye-labeled universal M13 forward or reverse primers. In some instances the
 10 sequencing reactions were also carried out using the dye terminators.

Example IX: Identification of Gene Sequences

The FASTA, Pearson and Lipman, "Improved tools
 15 for biological sequence analysis," *Proc. Natl. Acad. Sci. USA* 85:2444-2448, 1988, incorporated herein by reference, and BLAST, Altshul et al., "Basic local alignment search tool," *J. Mol. Biol.* 215:403-415, 1990, incorporated
 20 herein by reference, sequence programs were used for sequence data compilation and to search for sequence identity, in both the nucleic acid and amino acid coding domains. Some of the searches were carried out at the National Centre Of Biotechnology Information (NCBI) using the BLAST network service. Sequences were aligned and
 25 formatted using the eyeball sequence editor program, ESEE. Cabot and Beckenbach, "Simultaneous editing of multiple nucleic acids and protein sequences with ESEE," *Comput. Applic. Biosci.* 5:233-234, 1989, incorporated herein by
 reference.

30

Isolation of cDNA clones:

Approximately 12,000 independent cDNA clones
 derived from a cDNA library for the 30 day old kitten
 visual cortex were screened with a kitten visual cortex
 35 specific cDNA probe. This probe was prepared in such a
 way that the sequences also expressed in the adult visual
 cortex were removed by subtractive hybridization. 200 of

655240-090000

the total screened clones hybridized to the subtracted probe (Figure 2). As the signal intensities are likely to represent the abundance level of the corresponding mRNA, the clones with strong signal as well as those with weak
5 signal were isolated and individually grown for miniplasmid preparations. The plasmid DNA was isolated from each clone and digested with XhoI and HindIII restriction endonuclease to release the cDNA inserts. The digested DNA was electrophoresed on 1% agarose gels and
10 bidirectionally blotted to nylon membranes using the procedure of Smith and Summers. Smith and Summers, "The bidirectional transfer of DNA and RNA to nitrocellulose or DBM paper," *Anal. Biochem.* 109:123-129, 1980, incorporated herein by reference. These blots were then probed with
15 gel-purified twenty cDNA inserts (randomly chosen) radiolabelled by the oligo-labeling procedure. Feinberg et al., "A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity," *Anal. Biochem.* 132:6-13, 1983, incorporated herein by reference.
20 This was done to determine if any of the isolated cDNA clones were in multiple copies. One cDNA clone pKVC18 hybridized to twenty different cDNA clones and was therefore present in 10% of the purified cDNA clones. Seventy five percent of these clones were found to be
25 represented in single copy and the remaining 15% were in two to four copies (data not shown).

In order to verify whether the identified clones were truly representative of the mRNA abundance in the visual cortex of kittens and felines, we tested 50 of
30 these clones using Northern blot hybridization. Total RNA was prepared from the visual cortex derived from a different group of 30-day-old kittens and adult felines. Fifteen micrograms of each RNA was electrophoresed through 1.1% agarose gels containing 0.66 M formaldehyde and
35 blotted to nylon membranes using the procedure described by Thomas. Thomas, "Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose," *Proc.*

Natl. Acad. Sci. USA 77:5201-5205, 1980, incorporated herein by reference. The blots were hybridized with the riboprobes synthesized from the individual cDNA clones. Among the 50 tested clones only one clone was found to be expressed in similar levels in kitten and adult cat visual cortex. As shown in Figure 3 for eight of these clones, the hybridization signals were much more intense in the lanes containing the 30-day-old kitten visual cortex mRNA relative to those in the lanes containing the adult visual cortex mRNA. Probing a similar blot with a ubiquitin probe (obtained from a cat visual cDNA library) confirmed the uniform loading, transfer and integrity of both the kitten as well as adult visual cortex RNAs (data not shown). The band intensity for each lane in the resulting autoradiogram was scanned using the NIH Image program (version 1.46). Comparison of the band intensities for each probe in the lane containing kitten visual cortex mRNA with that of the adult visual cortex mRNA indicated that the signals were either unique to or at least 4- to 25-fold higher in the kitten visual cortex mRNA. This indicates that these clones detected RNAs that were either entirely specific to the 30-day-old kitten visual cortex at the sensitivity of Northern blot analysis or were at least highly enriched in the kitten visual cortex in comparison to the adult visual cortex.

We were interested in identifying the encoded product for these cDNA clones. Therefore we determined the sequence of approximately 400 nucleotides from both ends of 132 of these cDNAs. The open reading frame was identified at one end for 90 of these clones and translated to amino acids using the eyeball sequence editor (ESEE) program. Cabot and Beckenbach, "Simultaneous editing of multiple nucleic acids and protein sequences with ESEE," *Comput. Applic. Biosci.* 5:233-234, 1989, incorporated herein by reference. The amino acid sequence was used to search the EMBL release 28 DNA database using the FASTA program. Pearson and Lipman,

"Improved tools for biological sequence analysis," *Proc. Natl. Acad. Sci. USA* 85:2444-2448, 1988, incorporated herein by reference. Twenty of the ninety sequenced cDNA clones showed strong identities with previously known sequences. The other 30 clones did not show an open reading frame in all three reading frames but the 3' ends contained the complement of the poly A tail in the mRNA. We searched the EMBL DNA database at the nucleotide level for these sequences. Seven additional cDNA clones were identifiable. Based on these identities it was established that these sequence identities were in the 3' regions of the sequences in the database and contained the last portion of the coding sequences. These identities are shown in Table I. The scores are the measurements of the degree of identity among the matched regions. It also takes into account the gaps that are created in order to match the corresponding sequences. The resulting scores for all random matches in the polynucleotides are below 80 and the true matches are always greater than 80. All identifiable matches were further examined for their accuracy using the ESEE program, Cabot and Beckenbach, "Simultaneous editing of multiple nucleic acids and protein sequences with ESEE," *Comput. Applic. Biosci.* 5:233-234, 1989, incorporated herein by reference, which allows for the manual handling of the corresponding sequences, thus allowing for examination of the amino acid matches together with the nucleotide matches. SEQ. ID. NOS.: 1-93 represent those sequences which did not demonstrate identity with known amino acid sequences. SEQ. ID. NOS.: 94-119 represents those sequences which did demonstrate identity with known amino acid sequences. (See Table I.)

Example X: Construction of Subtracted cDNA
Library for the Differentially Expressed
mRNAs and Screening with Subtractive Probes
of the Dark-Reared Cat Visual Cortex

5 A subtracted cDNA library for the 30-day old kitten visual cortex was constructed with some modification to the original procedure used for the synthesis of the subtracted probe. In order to establish a renewable source of material, we first constructed

10 unidirectional lambda Zap cDNA libraries for both the 30-day kitten visual cortex and the adult cat visual cortex. Double stranded cDNA (dsDNA) was isolated from the 30-day kitten visual cortex cDNA library and the cDNA inserts were released by restriction digestion of the

15 cloning sites. Single stranded DNA was purified from the adult cat visual cortex cDNA library and photobiotinylated. One microgram of digested dsDNA from the 30-day kitten visual cortex cDNA library was then hybridized twice with 10 micrograms of photobiotinylated

20 single stranded DNA from the adult cat visual cortex cDNA library. After conjugation with streptavidin, the biotinylated fraction of the complex was removed and the remaining unhybridized double stranded cDNA inserts were cloned into the appropriate sites of the Lambda Zap

25 vector. This procedure resulted in a 30-day old kitten visual cortex specific subtracted library.

 Here the mRNA pool (20 ug) derived from the control tissue is photobiotinylated and the mRNA pool (1 ug) from the dark-reared 120 kitten visual cortex was

30 converted to [³²P] labeled antisense cDNA using the reverse transcriptase. The antisense cDNA was hybridized to the biotinylated normally reared 120-day kitten visual cortex mRNA. During hybridization, the sequences common to both mRNA pools form hybrids while the sequences

35 expressed in abundance and uniquely in the dark reared visual cortex do not hybridize to any biotinylated mRNA. The biotinylated sequences and their hybridized complements were then conjugated to streptavidin and

658340 40510660

removed by phenol/chloroform extraction. The remaining antisense [³²P] labeled cDNA which constitutes the subtractive probe was then used to screen the 30-day-old kitten visual cortex-specific subtracted cDNA library.

5 Eleven cDNA clones that hybridized uniquely to the dark reared-specific cDNA probe were partially sequenced. These sequences are represented by SEQ. ID. NOS.: 121-132.

Example XI: Administration of the Polynucleotides

10 Full length sequences are cloned into an HIV-1 construct as described in U.S. Patent Application Serial No. 08/213,799. The vector is then inserted into the visual cortex of an adult feline over four months of age
15 suffering from amblyopia. After the infusion of a therapeutically effective amount, the previously deprived eye is opened and the previously opened eye is sewn shut. The feline will subsequently recover function in the previously deprived eye.

20 From the foregoing, it will be evident that although specific embodiments of the invention have been described herein for the purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention.

25

Claims

1. A cDNA library, comprising polynucleotides isolated from a visual cortex of a kitten about 24-35 days old.

2. A cDNA library, comprising polynucleotides differentially expressed between polynucleotides isolated from a visual cortex of a kitten about 24-35 days and polynucleotides isolated from a visual cortex of an adult feline.

3. A cDNA library, comprising polynucleotides differentially expressed between polynucleotides isolated from a visual cortex of a dark-reared adult feline and polynucleotides of a visual cortex of an adult feline.

4. A cDNA library, comprising polynucleotides commonly expressed between cDNA libraries according to claim 2 and claim 3.

5. The cDNA library of claim 1, 2, or 4 wherein said kitten is about 25-30 days old.

6. The cDNA library of claim 1, 2, or 4 wherein said kitten is about 28 days old.

7. A cDNA library, comprising polynucleotides isolated from the visual cortex of a dark-reared adult feline.

8. A composition comprising an isolated polynucleotide having a sequence designated as one of:

SEQ. ID. NOS.: 1-132

or allelic variation thereof or complementary sequence thereto, or portion thereof at least 15 nucleotides in length.

668240-209T0E60

9. The composition of claim 8 wherein said portion of said polynucleotide is at least 50 nucleotides in length.

10. The composition of claim 9 wherein said the portion of said polynucleotide is in the range of about 50-100 nucleotides in length.

11. A composition comprising an isolated cDNA displaying at least 90% homology with the coding region of a polynucleotide corresponding to a sequence designated as one of:

SEQ. ID. NOS.: 1-132.

12. The composition as in claim 11 wherein said homology is at least 95%.

13. The composition of claim 12 wherein said homology is at least 97%.

14. The composition of claim 11 wherein said cDNA encodes a cell membrane associated protein.

15. The composition of claim 11 wherein said cDNA encodes a neurotransmitter release and processing associated protein.

16. The composition of claim 11 wherein said cDNA encodes a cell or tissue remodeling associated protein.

17. The composition of claim 11 wherein said cDNA encodes a cytoskeletal protein.

18. The composition of claim 11 wherein said cDNA encodes polypeptides associated with mRNA transcription and processing.

662240 20570550

19. The composition of claim 11 wherein said cDNA encodes polypeptides associated with energy, metabolism, and mitochondrial function.

20. The composition of claim 11 wherein said cDNA encodes polypeptides associated with neural plasticity.

21. The composition of claim 11 wherein said cDNA is at least 50 nucleotides in length.

22. The composition of claim 21 wherein said cDNA is about 50-100 nucleotides in length.

23. A composition comprising a human gene, said gene being capable of hybridizing to a sequence designated as any one of SEQ. ID. NOS.: 1-93, 120-132, or to a sequence complementary thereto, under hybridization conditions sufficiently stringent to require at least about 80% base pairing.

24. The human gene of claim 23 wherein said hybridization conditions are sufficiently stringent to require at least 90% base pairing.

25. The human gene of claim 24 wherein said hybridization conditions are sufficiently stringent to require at least 92% base pairing.

26. An antisense polynucleotide capable of blocking expression of a gene product of any one of the sequences of claim 23.

27. A triple helix probe capable of blocking expression of a gene product of any one of the sequences of claim 23.

09301507 043999

28. A composition, comprising a nucleic acid molecule according to any one of claims 1 to 27, in substantially purified form.

29. A construct, comprising a vector capable of directing the expression of a nucleic acid molecule according to any one of claims 1 to 25.

30. The construct of claim 29 wherein the vector is selected from the group consisting of retrovirus, adenovirus, herpes simplex virus, and vaccinia virus.

31. The construct of claim 29 wherein the vector is selected from plasmids and amplicon vectors.

32. A composition, comprising ex vivo mammalian cells carrying a construct according to claim 29.

33. A method of treating warm-blooded animals for neurological disorders, comprising:

administering to a warm-blooded animal a therapeutically effective amount of a composition comprising a polynucleotide, according to any one of claims 1-27, in combination with a pharmaceutically acceptable carrier or diluent such that said neurological disorder is treated.

34. The method of claim 33 wherein said neurological disorder is selected from the group consisting of Alzheimer's disease, depression, manic depression, ischemic brain disease, epilepsy, schizophrenia, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, and AIDS neurodegeneration.

35. The method of claim 33 wherein said neurological disorder is selected from the group consisting of stroke, traumatic head injury, and traumatic spinal cord injury.

09301507.04399
668340.20510550

37. A method of enhancing learning and memory of warm-blooded animals, comprising administering an effective amount of a polynucleotide according to any one of claims 1-27 in combination with a pharmaceutically acceptable carrier or diluent, such that learning and memory are enhanced.

39. A pharmaceutical composition, comprising any one of the polynucleotides according to claims 1-27 in a pharmaceutically acceptable diluent or carrier.

SEQ. ID. NOS.: 1-93 and 127-132.

42. A composition as in claim 40 wherein said
s encoded by a sequence designated as one of
SEQ. ID. NOS.: 11-20.

43. A composition as in claim 40 wherein said peptide is encoded by a sequence designated as one of

SEQ. ID. NOS.: 21-30.

44. A composition as in claim 40 wherein said peptide is encoded by a sequence designated as one of SEQ. ID. NOS.: 31-40.

45. A composition as in claim 40 wherein said peptide is encoded by a sequence designated as one of SEQ. ID. NOS.: 41-50.

46. A composition as in claim 40 wherein said peptide is encoded by a sequence designated as one of SEQ. ID. NOS.: 51-60.

47. A composition as in claim 40 wherein said peptide is encoded by a sequence designated as one of SEQ. ID. NOS.: 61-70.

48. A composition as in claim 40 wherein said peptide is encoded by a sequence designated as one of SEQ. ID. NOS.: 71-80.

49. A composition as in claim 40 wherein said peptide is encoded by a sequence designated as one of SEQ. ID. NOS.: 81-90.

50. A composition as in claim 40 wherein said peptide is encoded by a sequence designated as one of SEQ. ID. NOS.: 91-93.

51. A composition as in claim 40 wherein said peptide is encoded by a sequence designated as one of SEQ. ID. NOS.: 121-126.

52. A composition as in claim 40 wherein said peptide is encoded by a sequence designated as one of SEQ. ID. NOS.: 127-132.

658340-20960550

53. The composition of claim 40 wherein said peptide is about 100-150 amino acids in length.

54. The composition of claim 40 wherein said peptide is at least 130 amino acids in length.

55. A composition, comprising a recombinant binding partner capable of specifically binding a gene product encoded by the coded sequence designated as one of:

SEQ. ID. NOS.: 1-132

or a sequence complementary thereto.

56. The composition of claim 55 wherein said recombinant binding partner is selected from the group consisting of: antibodies or fragments thereof, peptides and small organic molecules.

09301507.042399
668240/29510860

SEQUENCES CHARACTERISTIC OF
GENES CONFERRING NEURAL PLASTICITY

Abstract of the Disclosure

The disclosed invention generally relates to newly identified polynucleotide sequences capable of conferring neural plasticity to neurons. Additionally, this application encompasses the complete gene sequences, the polypeptides associated therewith, and methods of using. These methods include the use of the sequences for gene therapy, including the treatment or cure of genetic diseases, for the treatment of degenerative disorders, for the treatment of neuron damage, and for the treatment of learning disorders. Additionally, these sequences are useful to enhance memory and learning capacity.

WW/MSD-3/2318401/V2

668240 40510560




FIGURE 1

09301507 042899



FIGURE 2




FIGURE 3




FIGURE 4

SEQ ID. NO.: 1

pKVC43:

CCTGGCTGCCTGTGCCTCAACCCCACTCCCAGGGAGACCAAAAGCCTTCATACATCTGAA AT

SEQ ID. NO.: 2

pKVC2B:

GCGACGGACGAGATGTCTTCGGTGTCTTGCGTTCGCTACCAGGTCAAATGCAAATCTTCGTGAAAAC
CCTGACgGGCAAGACCATCACCC

SEQ ID. NO.: 3

pKVC15:

TTTTTTTTTAATTGAGAAAGACATAATGGTTATGGCATTGGCTTGAAACCAGTTAAACACCGTTTCGATT
CCTTCCTTTCTTATTTTAATAGTACGTtAAGTTGGCTCTTCAAAT

SEQ. ID. NO.: 4

>pKVC24BR

poly(T)ATCCATACTTGCTATTTATTTAGGCTTCTAGTTTGAACAAAAGGNCAAGAGTTAAAAAAT
GCCAACATTTCAAGGACCCTTGTT

SEQ ID. NO.: 5

pKVC26B:

CTTCCCCCACTCATCCCTGCTCTGGTCCCTTGTgCCCCCTTGGCCCTTTACCCCAAGCACCCACCCACAG
ACTGGGGACCAGCCCCCTCTCCTGCCTATGTCTCgCCCCAAAT

SEQ ID. NO.: 6

pKVC50B:

CCTTCCCTTCCTTACTTTAATAGTTCGGTAGTACGGANGTTAAATCTTCAGGTCGGTGGTACGCAGCCG
GGCAACCATGCAATGGATTNAAGGTNGGTAATGGTACAATTGGCCTATGCCCACTTT

SEQ ID. NO.: 7

pKVC85B:

CTTTAGAGCGCACTCAGGGGCACTTGNAAGGGCTTCTCACGAGCGTGGCTGTGGCCATCTGTGGAAAGA
GCTTCTCGCAGTGNTCGGTNGNNTTATCCCCACGCCCNTAGNGCACTACTC

SEQ ID. NO.: 8

pKVC100:

TTAGTTTCACATTCAAGGGGCTTATGAAGAGATGCAAGTCAGGATACATAGGCTTGATTC
TTGGCAGCTTAaTGAGTaTTCACtGAGGCACTtG

SEQ ID. NO.: 9

pKVC94B:

CCGCCTGATATAGACACTTCGTAGAGCGTAGTTTGACTATTCTATACGTTTCTATTTATTGATGAGGA
TCCTAAA

FIGURE 5A

SEQ ID. NO.: 10

pKVC90B:

TTTATTATGCACACGTTGTTCAAATAAACAGTGTGGGATGTTAAGACTATCAATTAATGGTGGGATTA
TGTTTGGCATTATTATTNNTTATAAATATATATTTTTCTGAATGTGTCCTGAGNTCAAAGAGGTTGGG
GGNGGGGGNG

SEQ ID. NO.: 11

pKVC91B:

TTTCCTTGGGTTGCTGGTTGGATTAATCTTTAATAACAATATATAGAATTGTAGACTGATGTTTTAGTG
TTTTTCCAACACACAAACATAAAAAATAAAAACAAGTCGGACCGCTACTTCTGTGTAAATCAAGATCNTT
GGGGAA

SEQ ID. NO.: 12

pKVC101B:

CCTGGCCAGCGGGCAGGGCCACGAAGGCAAGATCGGTCGTTGTGCTTGTGTTTTCCAAGGAGACGANCC
NATNANCTGTAAATATGTACACGTNTCTGTCTGTGTGTCCTTCGNGGNAGG
ATGGTCGGNTCTATTTAAA

SEQ ID. NO.: 13

pKVC103fB:

CCAAAATATATTTGGGCCAAATGTTCCGAGGATGAGTCAGGCTGTCCTTCGCGCGGGCGAGACGAAGCT
TCACACGGGACAAGATGGGATGGGTGGAGGAATGGATGGTCCCCCAAACA
ATGGGCTTANAANAATTAT

SEQ ID. NO.: 14

pKVC105:

TTTACTGACAAGCATGGGGAAGTGTGCCAGCTGGCTGGAAGCTGGCAGTGATACCATCAAGCCTGATG
TCcAGAAGAGCAAAGAATATTTCTCTAAGCAGAAGTGAGCGCTAGGCCTTTT

SEQ ID. NO.: 15

pKVC107:

CGGCTTCcTGGGCTTTATCGTATGAGCCCATCACATGTTTACTGTAGGAATGGATGTAGACACACGAGC
ATACTTTACATCAGCCACTATAATTATTGCCATTCCcTACCGGGGTGAAAGT ATTTAGTTGACT

SEQ ID. NO.: 16

pKVC1B:

GGAGCTTGAAGAAGAAGTTTTTTACCACCGTCTTTTTCTACTTTATACAGAAGTAGATATTCCTGCGAA
GAAGAATAATTTGGGGTAATATGCAAGCTAGTAGATGTGGCACAGCAAATC ATATAATAAA

SEQ ID. NO.: 17

pKVC5B:

ACCCACCCAGAGCCTGGAATCAGGATCCCAGGGTCTAGCCAGCCTGGGGTCCAGAACCCAGAATCCAG
CCTGTCTGAGCTGGACCTAGCAGCCAGAGTCTAGCCAGCCTCGCTCCAAGAGGGGCTCTGGTGGCCTA
GGTAGACAGGCCTGggTGGGGATCAATGAGTTGGTGCTAGGGCCAGGGCACCTCGACTCTGCTCCATAC
TG

FIGURE 5B

SEQ ID. NO.: 18

pKVC7:

CACCTTCCTGAAACACCTGTGGCTTTGACTTTGTTATTGATCCAGATTATTCTCCTTGCAATTGGGGAAA
ATATCTTTCATATTTCACTGTAAGGGATGGTTTTGCGAGAGTAAGTTAATGTCAAGACAACTGCCAAT
ACAAGAGCCCAATGATATTAATTACATGAGAAAAaGTA ACTA ATACATCC

SEQ. ID. NO.: 19

>pKVC55R

GAGAAAGAAAGAGATGTTTTATTAGCATTTGTTACAGCAACGgTGACGTGAAGGGTCGTCCGTGCACAG
CCACCCGAGCGGCAAGGCGTAGGCCAGAGCTGACACCCAGTATTTACACGAGTGCAGAACAGGATCACC
CCGAACCTCAAACAGAAGACTGAAAGTCACTTTACAAAAAGGTAAATAAAAA

SEQ ID. NO.: 20

pKVC13B:

GCTACGGTCGACATCACCATCTTTATCCCTTCCAGCCCTTTGCTGGGTGCGGGCCCTTGGGAAGATGCC
AAAGAGCCGAGCAGTGGTGGTGGCCAGCGGGCAGAGTGTCCCTGCTTGGGCCAGGAAAGCTTTACCTTC
TCTGAGCGCCTCTGCCTGAGAGATCGATGGTCTGTGGCTCTA GGAGACCACGTCTTGGAGTG

SEQ. ID. NO.: 21

>pKVC6R

poly(T)CCTTCTTTATTGAATGACTTTCAAGAgGTAATTACAGTTGAAGGTGACAAGTTAGAAAGGAG
AGGTGCCACTGAAGGCATAAGGCTGCTTGTAGACCCGGCTCTAGACAAGTGGCAGGAGAAGAAAGAGGG
TTAAAAAAGGCATGAGCGTGCAGCCACGGGGCA

SEQ ID. NO.: 22

pKVC16B:

GGCAGCACTCCTATTA AAACTGGAACCTACTGAGGTTTCCTCGTGTAAATTAGGGAACAGAGAAACACgt
tCCACGAGGGAGCCTCCAGGTCTAATTACCTGCAACCTCGCTGTACCTTGCTGGCGAGGAGGGAGCCAC
CAATAGCAATTACTAACGAATGGCTGAATTTCTTATAAGACCTAGGGAACCTGATGGGAACTGAATT
GCTAA

SEQ. ID. NO.: 23

>pKVC74F

TTTTTTTTTTTTTAATTTTTTTTAACGTTTATTTATTTTTGAGACAGAGAGAGACAGAGCATGAACGGG
GGAGGGGCAGAGAGAGAGGGAGACACAGAATCGGAAGCATGCTCCAGGCTCTGAGCCCATCAGCCCAGA
GCCCCAGCGGGCTCGAACTCACGGACTGTGAGATCGTGACCTGAGCCGAAGTCAGACGCCCAACCAAC
TGAGCCACCCAGGCGCACCATC

SEQ ID. NO.: 24

pKVC29B:

CCAGGTGACAGGGAGCCTGCAGGGAGGGTCTGGGTGTTCCAGGAGCCAGGGGAAGTGGGAATGGTGCA
GGCAGTATTGGAAGGAAGGCCAGTCAGTGGGACTGGCAGCTCAGACAGGCAATATGGGGAAGCATTGGA
GCTTGCACTCTCACTCTGGGGTTAGGGGTTGCACACTCAGCAATAAATAACTGTGTACACCAAATC
CTAAATATATCACTACAAA

FIGURE 5C

SEQ. ID. NO.: 25

>pKVC79R

poly(T)GTGTTAAGTGGTCTTTATTGGGGTGTACATTAGGTTATCTTCTTCATTATCAGTTCTTCAG
TTAATTGTACAAGTATGATAAGTTATTTTATATCTGACGTGGGAATTTAAATGTAAAATAAATACAAAA
TACATCTGTGGTTTAATGAACACTCAATGAAGAC

SEQ ID. NO.: 26

pKVC30:

ACAACAAGTGTGCAGGTGCTTTTGTGTGGAGTGTGTGGATCTGTTGGTGGGGCCGGGGGGCCAGGAC
TCAAGGAGGACCCCTGGAAGTGTACATGTGCGGGCACAAGGGCACCTACGGGCTGCTGCGGCGGCGGG
ACGACTGGCCCTCGCGGCTGCAGATGTTCTTTGCCAATAACACGACCAGGAGTTTGACCCTCCGAAGT
TTACCCA

SEQ. ID. NO.: 27

>pKVC7R

poly(T)ACACAGAACAAGAAATTTTATTATCTCGAATGCTGGTGCATAAgCAATAACAAGCTCATCAA
TTAGAGGAGGAGACAGAGGGAACTTCAGATACTGATGAGGATTTCTGGGCAGGTTTAAACCTTTAA
GATTGAGGCCATAATTGTtCAGTCTTTTTTT

SEQ ID. NO.: 28

pKVC32B:

CCTTGCCAAGGCCGAGGCTCCACAGGAATCAGAGTTGGGACGACNNNGAAGGAAGCGTTTGGCTTCAC
ATTCTAGAGAAAGAAGACCCCTACTGGGCTGCAGACCCCTCCAGGGCTGTAGGAAAGCTGCTGGACCTCT
TCTGCTTCTCCCCAACCCTCTGCCACTCTGCCAGTTACCAG TCACCAG

SEQ. ID NO.: 29

>pKVC45BR

TTCAGAATACTGTTTTTTTTTTTTTTTAAATTTGTTTTGGTTTGTGTTTTGTTTTAATTTAAAGAAAGGT
ATTTTGCTTGAGGAAAAATACTCCAGATTCATTTAATGAGAATCTTTGAAATGTATTTATCTTTAGG
GCATTTGGGGCAACTTTAATGCCTGTTGGCCTCCGGCCTTCCTGGAAATAAAAGGTCCAACGG

SEQ ID. NO.: 30

pKVC34B:

CCTGCCCCACGCCATCCTGCGTCTGGACCTGGCTGGCCGGGACCTGACGGACTACCTCATGAAGATCCT
CACAGAGCGCGGCTACAGCTTCACCACCACCGCCGAGCGGAAATTGTGCGTGACATCAAGGAGAAGCTC
TGCTACGTGGCCTTGACTTCGAGCAGGAGATGGCCACCGCCGCGTCTCGTCTCCTGGAGAAGAGCT
ACGAGCTGCCCCGAC

SEQ. ID. NO.: 31

>pKVC89BF

ATTGTGATAGAAGACCACGGTGGGTTCAANCANGTTGAAGNAGTTCCGCNTTCCCCTCCGGGGGAAAG
GTTGTGATGTCTNTTGGTNNTAAGTANTCACCCATNCATTGTTGACAAGGNTCANTCCCGAAGGGTCA
TTCTTGAGTAGTAGACCAATATTNTAAAAATAATTTNAATCCTT

FIGURE 5D

SEQ ID. NO.: 32

pKVC34:

AATTGAGAAAACATAATGGTTATGGCATTGGCTTGAAACCAGTTAAAGAGGGTTCGATTCCTTCCTTT
CTTATTTTAATAGTACGTAAGTTGGCTCTTCAAATGTGTGGTACGGAGGAGGACATCCATGCAATCATT
CAAGATTAGTTGTGGTTAATTCTACTATGGCCACTTCTCGCTTGGATGCGAAAGCTTCTCACACTATGA
AAA

SEQ ID. NO.: 33

pKVC36B:

ACGCTCGTTTTCCAAAGAGAAGAGCGTTGTTTAGAGTAGCGAAATTCGAAGGCTGCTTAGGCGCATTGT
AAAGCTGTTGGGGAAATAACTCCACAAGTTTCGTGAGTGGAATGTAGTGCTCGAAACACATTCTGCTT
TAAAAGGTTGTAACAAATACAAACAAATTTAAAAAAGCTCT CGAAAA

SEQ ID. NO.: 34

pKVC43rB:

CTGGAGCGCAAGTACTCCGTGTGGATCGGTGGCTCCATCCCGGGCTTGGTGTCCACCTTCCACAAGTG
TTGATCACACAAGCCGGAGTACGCGCGCGGTTCCGGCCCCCTTCATAGGCCACCGCAAAAACCTTTTAGGC
GGGCTCTTACNTTAGAGGCGGTACACACCTTCTTG

SEQ ID. NO.: 35

pKVC73:

TGGGCATCAAATGAAAGAGATACTTGCAAAGGCTCTTGAGGGGCAGGGAAAGGAAAGGAGGACTGTCTG
CTTTGGACCCTAAACTGGACAGGGACTAGGTATTTTTGATGTTATAAGTTGTCCTGCTCTAAGTTCAT
TTGAGTAGCAGACCTGACAAGCATTTGAGGTCAAACCCCTACCATGTGTAAAAA

SEQ ID. NO.: 36

pKVC79B:

GTCTTGATACAAAGCTTCTGTGCTAATCCAGACTATTTAGGCAGGGGCAATAGGGTGTAATGTATCT
GCTCTCTTCAAACGCGGCTAANGNTCTAGTCCATGTCCNCCNNGCAACCNCAANATCCCACNAGGGG
GNAGNTCG

SEQ ID. NO.: 37

pKVC81B:

CCCAGGTGAACAGGAACAGGTTTTCTCATAAAAAACAACAAAAATCCTTGCCATTCATTTTCTTACTT
GNATGTGGAATAATAGATCCGCCTTTATTGNTGAATAGCCTTAAACTTTTGGAGAATATTCCTTAGNA
AATTAGGGGGGNGGGGC

SEQ ID. NO.: 38

pKVC83B:

CATCTAGATANTCTTGGNGATTGGGGCCTCTAGNTGATTGCTCGAGCGGCCGCCAGTGTGTTTTAAAGA
CTGGCTCAGGGCCTGTGCGAGGTGCTGCTGGTGGTGACCAAGGAGGTGGAGGAAAAGGGCTGCTGGNCT
GCGGNACAGTACTGACCCCGCGGAGGTAGTAGCAACCAGGTCCACCGTACCCCTGCGAGTCCCCGCTG
CCAATCCCC

FIGURE 5E

SEQ ID. NO.: 39

pKVC87B:

CCACCAAGAAGCTGGACCTGTGGATGCTGCCTGAGACACTCATTATCCACCTGAAGCGCTTCTCTTACA
CCAAGTTCTCCCGCGAGAAGCTGGATACCCTTGTGGAGTTTCCCATCCGGGACCTGGAACCTCTCCGAG
TTTGGCATCAAGTCCGTAGGAACGAGTCGGCTCCGGAGCTGTACAAATACGCATCTCATCGNGGGNTNC
CATCNCATTNATGGGGG

SEQ ID. NO.: 40

pKVC104fB:

GGCGAATTGGGCCCTCTAGATGCATGCTCGAGCGGGCGCCAGTGTGCTCTAAAGCCAAAATATATTTGA
GCCAAATGTTCCGAGGATGAGTCAGGCTGTCTTCGGGGGCAGNAAAGGCTTCACACGGGACAAGTGGAT
GGNTTGGAGGAATGNATGNTCCGCAACCATGGGCT

SEQ ID. NO.: 41

pKVC104:

CTGACTGGCCCAGAATTTTTGAATACTGGAGGCAGTCTCATTGGCCTCCCTCATTAGACTCCAGGATTC
GGTCCAGCCCCGAGACCACTGTGGGCTCCTACCAGTCCAAAAGTCTAGGACCGCTTGACAGCCAGGAAA
GGAATTTTCTAGTGTTCTACAAAGGCCAATAGAGAGGGTGGGAGTGGGTGGGGTGAGGACCGGTGGCGA
GAGGGG

SEQ ID. NO.: 42

pKVC109B:

GCCAGATTTACATAAGAACATGCTTAACAGACGATCTTTTAGCTGACGTCTTACCAGNAATCGCCCAAG
TCCGCACGGTAAGTAAAGAGGAGGCCCGCCAGGTGAGAGTTTGTCTAGCAATAGGGTCAGGTCACTAAA
ACTGTAAATCCATTGCGAGAGGGGGACGCCTCCGCTCAAGCT TGGCTGGGCTTCGGC

SEQ ID. NO.: 43

pKVC89B:

GTCAAAGAGACCAAATCCCATATCCTCATCTGATTCTCCGACTCTTCCTTTGCTTCAACCTTGGCTGG
GGCTGCAGCAGCAGCAGGTGCAGCAGTGGTGGCAGCGGCCACGGGGGCAGCAGCCACAAATGCAGATGG
GATCAGCCAAGAAGGCCTTGACCTTTTCAGGCAAGTGGGGAAGGTATAATCAGGTCTCCACAGGACAA
AGGCCAGGACCCGCTTATTTTCCATTGGATGGATAGGAATGGGGGGCACTGNATGCAAACAGGNCGGGG
TTNACCCTTTCTGNAGGACCATT
TCA

SEQ ID. NO.: 44

pKVC115:

GCGCAGGCACAGCTGGTGAGGGGCGAGGCCGAGACGCCAAGGTGGCCACCATGGTCCGGAGTGCCTGC
AGGTAGTGGGCTTCGTACGAGCTTCGTGGGTTGGATCGGCATCATCGTCACCACGTCCACCAACGACT
GGGTGGTGACCTGCGGCTACACCATCCCCACCTGCCGCAAGCTGGACGAACTGGGCTCCAAGGGGCTGT
GGGCAGACTC

SEQ ID. NO.: 45

FIGURE 5F

pKVC20fB:

CAAACCCATGCATACCACATAGTCAACCCTAGCCCATGGCCACTTACAGGAGCCCTTtCAGCCCTCTTA
ATAACCTCAGGCCTGGCTATATGATTCCACTACAACCTCAACACTGCTGTAAACCCTTGGAATAACTACC
AACCTACTAACTATATATCAATGATGACGAGACATTATCAGAGAAAGCACATTCCAAGGCCATCATACA
CCTATCGTTCAAAAAGG

SEQ ID. NO.: 46

pKVC7B:

GCGCCCGCCGCGTCGCGCCGCCTACCGCCGTACCACCCGCCGCTCCTCTGCAACCTCAGCCCACCGG
GGCACCCGGCCAGGTCACTGGCGGCCAGGCGCAGCTCCTGGAGGAGAATGACCAGCTCATCCGCTGT
ATCGTGGAGTATCAGAACAAAGGCCGGCGAATGAGTGCCTCCAGTACCAGCATGTGTTACACAGAAAT
CTCATTTATTTGGCTACCATCGCAGATGCCAACCC

SEQ ID. NO.: 47

pKVC92:

AGACCAGCCGGTGACAACCACTAATCAAGTTCATAACTATATAGCGCCGCAATTCCCATGGCCTCCTC
ACTAAAGAACCTGAGTCACCTGTATCATAAATCACCAATCACCTGCACCGTTAACTTAAATACGAC
TTCTACCTCATCTTCCTTTAAATATAACAAGCAGTTAATAATTCTGCTAACACCCCGTAATAAACAT
TGCTAGTA

SEQ ID. NO.: 48

pKVC8: TGAGGTTGATTATTGTGGTGGTATTGTTCACTGTGTAGAAATAGTAGGAGTA

GATTTAAATAGATTGTTCAAGTTTTAATATTAGCCATAGAACTGGTTAGTATCTCAGTAGTTTCATGAA
AGCTTTTCTGTATTCTAATCTATTTTGAGAAATTTTCTCCCTTTTTTTAATTGTGTCTTACAGTTC
AAGTTTGTAGATTTTAATAAGCAACAATTTTAAAGATGCGGTAATCTTCCAATAATTTTATCCATC
TTTCATGGCCCCACAACCTGCATCTTTAAT

SEQ ID. NO.: 49

pKVC8B:

CTAACTGCATTCTCTCCTCGTTCATCCTTTGGGGCTGATTGATGAGCCCTTATTTCTTATCTCTAAAA
ATCAACAGCAAGGTCTACTTCACATGGCCACTCCAGTCCTTTGAGCTATAATCAGGATTATATACTTA
CCCTCAAATCAAAAGTTAAGAAAAAGGAAGCCCATAGCTAAGGCACTGAATCTTTTCTGACAATTTT
TAGAGGTAGAATTTTCATCATGCTGCAGAGAGAGAGAGAGAGAGAGAGAGAAGGAGGGGAGGGAAG
AGAAATGAAAGAG

SEQ ID. NO.: 50

pKVC14:

ATAATGGTTATGGCATTGGCTTGAAACCAGTTAAAGAGGGTTCGATTCTTCTTTCTTATTTTAATAG
TACGTAAGTTGGCTCTTCAAATGTGTGGTACGGAGGAGGACATCCATGCAATCATTCAAGATTAGTTGT
GGTTAATTCTACTATGGCCACTTCTCGCTTGATGCGAAAGCTTCTCACACTATGAAACTATTAACAT
GACTGCTGTTAATGAGATGAAAGAGCCCATGAGGAAATCGTATTTCAAGTTGTATATGCATCTGGATA
GTCAGAATAAC

FIGURE 5G

SEQ ID. NO.: 51

pKVC16:

TGGTGACACACGTCTTTCAGTCACCAAGTGGAGATCACCAGGAGCATCAGCAGGAAGAGCCAGTGGGCCC
ACAAGCTTAGCAAGTTGATCAGGATAGGGTTATTTGGTGGATAGACCATGAGTGTGAGGGACCTCCAC
TGGACACCACCCAGAGGCTCAGGATGCTTTTCGAGGGAGGAAAGGAGAAAGACCTCTACTGAGGGAAC
AGCTGGCCGTGTGTGGTGGGCTGAGGTGACGTACAGGGGCAGAGCTTTCGAGGGATTTTCAGATGATCC

FIGURE 5H

SEQ ID. NO.: 52

pKVC20rB:

TAAATAGAAACGTATAGAATAGTCAAACCTACGTCTACGAAGTGTCAATATCAGGCGGCGGCTTCAAATC
CGAAGTGGTGATTTGATGTAAAGTGATATTTTAGTTGGCGTAAGAAGCATACAATTAGGAAAAGTAGAGC
CAATAATTACATGTAGCCCATGGAATCCTGTGGCCATGAAGAAGGTAGATCCGTATACTCCGTCCGAGA
TCGTGAATGATGTTTCATAGTATTCTGGAGGCTTGAAGGAGTGTAAGTAGACTCCTAAAGAGATTGTA
ATAAATAGTGCTTGAAG

SEQ. ID. NO.: 53

>pKVC59BR

poly(T)GTTTTTGTGTTTTAAAAATGAGTTCTTTTAAACCATGTCATACATTCCCATACTGATATCG
CATGACCCNTTANAATAAAGGCAGGGGGNTTTACTAATGGGGGGGCGGGCCANACCCNCCATCGTTTCA
GCCAGACAGTTCAACCCGGGGNNCCTTGTTCTGCGGACCTCCGGGGNANGCCTTTCCTTTTCCAAAAA
GGGGGCCGNTCGGAGNATGNATNTNGAGGGCCCAATTAG

SEQ ID. NO.: 54

pKVC21B:

GCGCTCTGACCAGGCATCAGTTTTCTGGTGCTCTCTGGGCTAGCCTGGTGATGTAGGGCCAGGCAGAC
AGGCAGGCAGGGGCTGAACAGGGTTTCTCTGCTCCAGGAAGACCAAACACAGAGGACCTTACAGGCAGG
AACCCACAGACTGTCCCAACCCACACACTCCACCACCTGTGCCCTGTCCCATGTCTGAGCCAAGGCC
TGAGGTAGAAAGTCACCTGATCCTGTATCTCCATAGGGGCTGACTTT

SEQ. ID. NO.: 55

>pKVC61BF

poly(T)CCCNAGNGCACACNGGNGGCCNTAANNAGNGGNTCCNAGCNCGGNACCNAGNTTGAGGCATA
GCTTNAGNATTCNATAGTGNANCACAAATAGCNTGGGGNAATCANGGNCAAAGCCNTTTCCTGTNGAA
ATTGTNATCCNNTCANAATCCNCACAAATACGGGCCNGAAGCATAAAGNGTAAAGCCCCGGGGGGCCC
AANGNGGGNGCNAACTCACATTTAATNGCG

SEQ ID. NO.: 56

pKVC23:

GGGAAATGTAGTTTGGATGCAAAGCTGATTAAATTGGATCAAGAAAAATTGGAATTAATACATACAAT
AATGCATGCATTTATGGTTTCGATTTTATATATCCTTAGCTAGTTGGAAATGATGATTCCCACAACAA
GCATAACTCAGCTTGTTTCTGCTTACTGAGTACTTTCTCCTATGGTATATGTTGATAACATTTCTTCCA
TTATGTATGTTGCATAcgAGAGTTACAGTTACT GTGGAATCATAATTTT

SEQ. ID. NO.: 57

>pKVC9R

GTCACCATTAATGTCTgAATTTTAAACAGATTCTTGGACTGGTGGCTCATATCCATCAGCTCGCTCAA
CTTTAGCACCGGTCTCATCCCAGTAGCTTTTCCAGAAGTCTACCTTCACCATGAAGCTCCATGAGCT
TTCCCAATTCAAACCTTGGGCTTCTTCAGCATTTTACTTTTCTAACGAAGTCATCATGAAGTGGATAAA
TAGACTGACAAGCCTTCTCTATGTCTTTCCGATCTGTCTGGAATCAATTTATTGACAACCTTTTCAA
GTCA

FIGURE 5I

SEQ ID. NO.: 58

pKVC28B:

TCATAGCATTTCTTCTGCTTCTCCTGGATTATGTGCTACAAATGTGCTTTGGCTTTAGAAAGGGATGGA
TGAGAAGACAGAGCTGAGATCAACCTGGGTAGAAGCAGAAAGTTAAACCCTTTAAAAGTGCTGAACACA
GATTCGAATCCAAATGGTTCAAGCAGCCATGAAATCGCTCTTCATGAAGTGGGCTTAATTCTCTAGTTT
AAGTTCTTTTGATGGAATGAATTAATTAATGTGTCAGGTGGCTTATTTGTGGATGCATGATTGATGATG
TCATT

SEQ ID. NO.: 59

pKVC29:

CGGACCCGGACAGAAAGCAAATCCTGGAGCGCACCCAGCGTGCGGTGGGGCTGGCCGCAGAGCCCCTGG
AGAGAGCCGTGCGGgNCGGCCTCCCGGCAGAGGAGGCCGCCCGCTGCGCAGAGGTGTTGTTGGAAGAAG
CGAAAGATTTGCTCTCCGACTGGTTGACTCCACCCTGGGCAGCGAAGTTACGGACAATTCTATTTTCT
CCAAACTGCCCAAGTTCTGGGAAGAAGAATTCCACAGAGACATGGAAACCCTGAACGTTCTCCCTCCGG
ACGTCCT

SEQ ID. NO.: 60

pKVC38:

CGAATCTGTTGTAGCAGTTTCAAATGATTGTGTGGATATTGGATGTTTAACCTTTACCATTTGCTTTGT
ATCGACACATTTTTCATTTTAAGTGTTAACTCATGTAAGTTTACTTTAGGAATAATGCAAATCCAACC
TTCATCCAGTGATGAGAATAGCAGTATGATAGGAATTTGCTCAATGTGCTTTAAATGAGTAATTGCTTT
ATCTTTTTTTAGTATCTGATAGACTTTGCATGACACGGTACACTCCTAATTATGCATTCTTTAGTTTCCA
AATCTTAACCTAAGACATTCTATATTAAGTATGGGTAGCTGAG

SEQ ID. NO.: 61

pKVC48B:

GGTTTTGCAGGGGCAAGTGGGGCTGGGCCCCGCTGGGTGAGAACCCCGCCGCACACTGCAGTGGGTGCC
TGGACCCCGCAGCAGCGCTGAGCAGACGGTGGACTCTGGGCTGTGGCCTTTCTTGGGCCCCTGGGGCC
GGCTCTTGATATAGCTGGGGCTCATGGGCATGACCCCTTTTTTAAACCTTGGGTCTTAGGACACCTG
GGTTTACCCTCAACTAAGGGAGGGTGGGAAAGGGATTTACTTGGGGTCTCAATAATTTACGATATCCCT
TTAAGGTTGACCATTAAACTGTCCCA

SEQ ID. NO.: 62

pKVC51B:

CCTCTTAATAACCTCAGGCCTGGCTATATGATTCCACTACAACCTCAACACTGCTGTTAACCCTTGGAAT
AACTACCAACCTACTAATATATCAATGATGACGAGACATTATCCGAGAAAGCACATTCCAAGGCCA
TCATACACCTATCGTTCAAAAAGGCCTTCGATACGGAATAATCCTCTTTATCATCTCAGAGGTATTCTT
TTTCGCAGGCTTTCTTCTGGGCCTTTGTTACCACTCAAGCCTAGCCCAACCCCCCGTAGCTTAGGGGG

SEQ ID. NO.: 63

pKVC53B:

FIGURE 5J

SEQ ID. NO.: 69

pKVC69:

TGGCTGTCATCTGGAGGCTTCTGCCTCAGCTCCTGAAGGCTGCTCTCATTCTTCTCGCGTGCTCCCGT
CCATCTTCAAATTCTCAATGGCCCATCTTCTCAGCCTCCCATCCCTCTGCCTTCTTCTCTGTTTTAA
GGTTCATGTGATTAGATCAAGCCCACTGATCAAGTCTCCCTATTTTAAGGTCAGTTCTGCCATAGAACA
TAACATAATCACAGGAGTGACTGCACAGGCACGGGTTCTGGGATTTGGGCATGGAGTTGGGGG

SEQ ID. NO.: 70

pKVC74:

ACGCTAAGGACACCTTTTTTGTCTGACCTGATGTTATAGATGGCAACACCAAGTTCTAGAGCAATT
GAGAGACTTGTCCAAGGTCACAGGATGGCTTCACTTCAGCCAATATATAGTTGCAGTGACAGTATGTG
TGCTCTCTGAGGGGTTACTGAAAACCCCTGTCAAATATTTCTGTGGACACTCAGCCTTTAACTCCCA
AGCCTCATGAAGAACTTATTGGGGGGGGGGGCGCCTAAATAATTCAAGTCGGTTGAGCGTCTGACTTCG
GCTCAGGTCATGATCTCACAGCTC GTGAGTTCGAG

SEQ ID. NO.: 71

pKVC86:

TGCCTAGAATCATTGTTCTGTGTGGAGGTGTTTTGTTTTGATAGAAACCGGCCAGTCTGAACCAGAAC
GAATGTTTCCCTTGTCTAATGTTCTCACAGAGAAATGGACAAGCGTTTTACAGGTATAAAAGGCACAAG
GAGGAACCTATTTTTGGTCAGAGCATTGGGGAAGTAAATCACAAGGCAAAATAGATCTGTTTGTTGTTT
GTTGCGGGAGGAAGTATTAATAAGCAAATCAAATGCCTTGATGATCTCCAGTGTTATAATTATAGATC
CTAACTTTGCAAATACATGTAG

SEQ ID. NO.: 72

pKVC96B:

ACTGGACCAAAATTGGTGTTTGTTTTAACCTTGACTCTTCTTTTGATTATTTCTAATGCTACAAGAATG
CTGTAAAGTGTCTTCTACAATGATGTAGCCCTGACAAGACATGTTTGGCAGTGTATAAAAATTAGGTAG
GATTGTGCACTGATTGACCATTTGTGAAATCTTTTCTCAGTGGTAAGTGCATTCTCTAATAAAATTTAT
GNAGGTGAAACAATCTTTGGNGCAATGGACCACTCATGCATCCATCCC

SEQ ID. NO.: 73

pKVC97B:

AACAGCCCCACTATCAGCACCCAAAGCTGAAATTCTTTCTTAACTATTCCTTGCCAATACCAGNAAAG
CAACCCCATAACTTTTATAATTATATATTGCATATACCCATACTGTGGCTTGGCCAGTATGTCCTTAT
TTCCACAAAAAACCAAGTAANAAACCCCAAGTACCACAACCCAAAACACACAATGTAAATCACTCT
ATTAACCACANACCCACCCAGGTTGGGTATTATACCCATGGTNCATAAGGACATACTATGT

SEQ ID. NO.: 74

pKVC103rB:

CGCTGCATCTTTTTCTATGCTCTCCCTGCTGGCGCTGATGGGAGATACAGACAGCAAAACGGACAGCTC
GTNTCATGATCGACTCGGACCCTCTGCGNCTGCATGAGGCACCACTATGTTGNATTCTATCAGCTCACC
CGTTGNTACAAGTGTAGNCTCAAAGGAAGAATAGTGGGAGTCTTCTGTGAGACCTATCTGAATCCCCGN
NTGGCCCTGAGNTTCCAGAGGGNCCTGGTCGTCCTAGCAGGGTTCAAGNAAAGGGGGCCCGCN
CATGGCAGTCTTGGNCAGNAGNAANGGANTTGGNCCCAACCCNNTTGGTTCCCAACCCA

SEQ ID. NO.: 75

FIGURE 5K

pKVC103:

CGGCCACTGGTCATCAGATGAGCATTTTGTGTGTTTGAAGCTAGTAGCTATAGAAAAGATAGTTGTGCC
CTGATAAAGTAGCTTTTTAAAAAAGTTTGGGTAGTTTCACATTCAAGGGGCTTATGAAGAGATGCAA
GTCAGGATACATAGGCTTGATTCTTGGCAGCTTAATGAGTCTTCAGAGGCACTGAAGGTGGAAGGGTG
GAGTCCAGTAACTGCTCTGGAGCAGTGACTTCCCAATTCTGACGATCTCAACATTGTTTCTGAAGGACG
TTGCCATCTTGACACAGGAACGTGCTGTGGGGTGCCTGGCAGTGTCTGAGTAGTAGACTT

SEQ ID. NO.: 76

pKVC104rB:

CGCTGCATCTTTTTCTATGCTCTCCCTGCTGGCGCTGATGGGAGATACAGACAGCAAAACGGACAGCTC
GTTTCATGATCGACTCGGGACCCTCTGTCGTCTGCATGNAGGGCACCACTACTGTTGGATTCTTATCA
GNNCAACCCGCCNGNTGCAAAGATGNTAGACTCCANAAGAGNAAGNAATNAGTTGGGNAGGTCNTT
CCTGCTGNAGAACCTAATTCNTTGCAATTCCCC CCCCCCCCCGG

SEQ ID. NO.: 77

pKVC107fB:

ATTACAACATCTAGAAGGCTTTCATCATACGATACAAAGCTCAGTTACAAATGTGCATCCTAGTATTTG
GAAACTAATACCTCTCTTAATGTAACATGAAAAATTATTTCTTATGTCCTTTTTTCAGGACTCCTCTT
TTATTTTTTGGTATTTTATCTTTTATGGCCACCTTGGCCTTCTGGCCAATGTGTTATGCAGTGAAAATG
CTTGTGGGCAGAGGATGCCCTACAGCGCAAAAATACCGCGCACATGGGTTTCCCAGGTA

SEQ ID. NO.: 78

pKVC107rB:

TTTTGTTTTATCCGTTTATTAGTACATGGGCGTCGGGAGGATGATTTACTCATCATCTTGTATTACCAG
AGGTAGAGCATAATGCCATCTGCTAGGGATCCAGTTCGACAGCACCTCAAAACACTAGTCTGCTCACTC
ACCCTATAGGGCTTGNTCATTCCACTTGGGATGGAAGACAACAGTGCCTTTAATGCAAATGGGCCCCAG
GCAAGGAATTAACCATTGGCTTCATGGCTCATGAAGGAATACAGNCNNATTTAANGCGNGGCAGGCAGG
AAGCCTTTGNGCTA

SEQ ID. NO.: 79

pKVC124:

CTAAAGTGGCTgAACAGTATACCCACCCCTAGCCGGCAACCTGGCTCATGCAGGAGCATCCGTAGACCT
AACTATTTTTTCACTACACCTGGCAGGTGTCTCCTCAATCTTGGGTGCTATTAATTTCACTACTACTA
TTATTAATATAAAACCTCCTGCCATGTCCCAATATCAAACACCTCTATTTGTCTGATCAGTCTTAATCA
CTGCTGTCTTACTACTTCTATCACTTCCAGTCTTAGCAGCGGGAATCACTATATTATAACAGATCGAA
ACCT

SEQ ID. NO.: 80

pKVC24B:

GCCGGGAGCCGGCCTTTGGGCCGNGGGCGGAGAGGCCCGGACGGTCGAGTGCTTCTCCTGACTGGTG
CGAGAAGAACATTTTCTATATACTTCCAGGTGCTTTTATATTCTTTTCGAGAAGAAAATAAAATTATGA
ACTCAGGATTTTGCAAGTATTCTGTGTTTCTCCTGGAGTAGGTAGTCCTTCTTCTTTTACCCAGCCACT
TTCCCTATTCTTGAAATGTGGATCTCTTCTCTACATGTTTTACCTCCATGATTGGATTGGAAAAAG
CTGCTTTTCTTTTGGTTCCACTTTTCAGATTCAACATAGAGAAGCTCCTAGGATGCAGTCGTCTTTCTG
AAGCGCTTCCAGGGAAGAAAGAAAGAAACT

FIGURE 5L

SEQ ID. NO.: 81

pKVC25:

AGGTCTTAANCCCAACCCCGTCCCACCCACAGGGTNCAGCGTGGTGA
CTACAGGCGACCCTCCCTATGTCGGGTCTAGAACGCCCCCAGCTGGAACGAAGGGAAGAAGCTAATTACAGTGTCTTCCTTTGCACTGAC
CNNCCCCCCCCCGCCCCCGCCACCAGTTCAGTCCAGGAGGGGACTTGTAGCCCGTAGCCCATCTT
CCCCACTATCCTGGCGTGTGGGCTCGTGAATGCCTCCTAGCCAAATCACTAGAGTGCAGTGACCCAG
CCTCCTTCCTGTGCCAAGATG

SEQ ID. NO.: 82

pKVC40B:

GCAACAAGGAATGAGACCCCCAATGCCGCCTCATGGTCAGTACGGTGGTCATCATCAAGGCATGCCAGG
TTACCTTCCTGGTGCTATGCCACCGTATGGGCAGGGACCGCCAATGGTACCCCTTACCAAGGTGGGCC
TCCTCGACCTCCGATGGGAATGAGACCTCCTGTAATGTCGCAAGGTGGCCGTTACTGATCTTACTTCAT
CCAATCTAATAGGTTTTGAGATTAAACCTTTCTCAACTTGTGCTGGTTTATATAGCCAAGCTTCCGTC
AATAAGGCTTTATTGTTGACTTTAACAAACATTATATTACCACATACCAGGGACTATTGGACAATTATT
TTACAAGGGGAAAAATT

SEQ ID. NO.: 83

pKVC43fB:

CCTGGCTGCCTGTGCCTCAACCCCACTCCCAGGGAGACCAAAAGCCTTCATACATCTAAAATTGGGGGG
GGGGGGGGGGACAAAAAGGGGGCCACGATGGCAGACCATTGAAATAAAACAAAAAGACCAAGTTTT
AAGGCGAGAGTTTAAAAAAATTTGGACTACATAATTTACACCAAGGCAATGTTATCACCTGCGCCTG
TTTGGACTTGGGCGGGGACTGGCCCTTCTCCTCAGGGGGAAATGGGGTGGCTTTTGGGAAGGCAAGGGA
CTTCCTGTAACAATGCATCTCAGGGTATTTGGAATGACTATTAATAAAAAAAGGGCCAATGTTACAGTC
AAGGTCCTGGGCCCCA ACCTTGGAACCTTTTGGGGGT

SEQ ID. NO.: 84

pKVC55B:

CCCAAACATCTACAAACACAATAACACCAGAAAAATAAAACAAAACATTTAGTCACCTTATAAAAGTAT
AGGAGATAGAAATTTAACTTGGCGCTATAGAGAAAGTACCGCAAGGGAAAGATGAAAGATAAAATTTAA
AGCACCACACAGCAAAGATTACCCCTTGTACCTTTTGATAATGAGTTAGCTAGAACAACCTAACAAAG
AGAACTTCAGCTAGGCCCCCCGAAACCAGACGAGCTACCCATGTACAATCTATTTTCAGGGGTGAAACTC
CGTCTATGTTGCAAAATTAGTGAGAAGGTTTTTGGGTAGAGGTGAAAAGCCTATCGGGCCTGGTGGTAG
CTGGTTGCCCCGAACCGGATTCTTAGTTTCACCTTTTAACTTTCT

SEQ ID. NO.: 85

pKVC57B:

GC⁵GGAAGCAGTGATCCTCCAGCCTGCAGAGGCCCCCTTCCCCAGCCTGGCCCAGCTCCGGCCCCGGCCCC
GGGCTGGACTCCTCCTACAGATTTATTTGACGTTTTATTTTGGTTTCCCCACACCCCTCAATCTGT
CGGGGAGCCCCCTGCCCTTCATCTTGCTCCCTTGGCCAGGAGTGAGTGACCCATGGCCTTGGCGAAATTG
TCCTCCTCTTCTCCCCTCGCACTACAGTCTGGTCCGGGAGAGGGTGGCGGGTGCTGCTTGTGGTTTAG
TGGGTTTTGTTTGGTTTTTTGTTTTCTTTCT

FIGURE 5M

SEQ ID. NO.: 86

pKVC60fB:

AAAGGGTGGGGCANTTGATGCTGGTTTCTTCCTCTGCGTTTTCCGTAATTCCTTCTTACTAGGGCTTTA
TAATTCCTAATTTTTCTTGGTTAAGTAGTAATATAAAACACAATCAGGAACACTCTTTCTTTCCAAGTAG
GATGCAATTAGTCCAAAGTTTTTTGGATGCTGGATAAACTTGTCTTAAAGATCTCCTTCTCGTGGTCA
GTCCAAACATTTCATAAACTGCCTATCTTTATAAACTTTTCATAGGATCTTCATGAGTCCATTTCATGTTG
ATGAATTTGACTCGTCTCTGTTCTGCATCAAACATCATAGGTGGGATCACAGAGAGTTGCCGCATTTGT
TTCTCATTATTTCTCCTTCTCAGAGAGCCCATCAATAATTTTCAG

SEQ ID. NO.: 87

pKVC60rB:

GTTTCCAGAAATTCGAAAACAAAGAGAACAACAAGAAAGGTTTCAGCGAGTTGGGCAGAGGGGAGCTGG
TCTTTCAGCCACGATTGCTAGGAGCGAGCATGAGATTTCTGAAATTATTGATGGGCTCTCTGAGCAGGA
GAATAATGAGAAACAAATGCGGCAACTCTCTGTGATCCCACCTATGATGTTTGATGCAGAACAGAGACG
AGTCAAATTCATCAACATGAATGGACTCATGGAAGATCCTATGGAAAGTTTATAAAAGATAGGCAGTTT
ATGAATGTTTGGGACTGACCACGAGAAGGAGATCTTTAAGGACAAGTTTATCCAGCATCCAAAAAACTT
TGGGCTAATTGCATCCTACTTGGGAAAGAAAGGGTGTTCCTGATTGTGTTTTATATTACTACTTAACCC
AGGAAAATGGGGATTATTAAAGGCCTAGTAAGGAGGGATTTACGGGAAACCGCAGAGGAAGGAACCCGC
AGGCAATTGCCCCCCTTTGG

SEQ ID. NO.: 88

pKVC63B:

CCTACCCGGTTTTGGGATAATCTCACATATTGTTACCTACTATTCAGGTAAAAAAGAACCCTTTGGCTA
CATGGGAATAGTTTGAGCCATGATATCAATCGGCTTCTGGGCTTTATCGTATGAGCCCATCACATGTT
TACTGTAGGAATGGATGTAGACACACGAGCATACTTTACATCAGCCACTATAATTATTGCCATTCCTAC
CGGGGTGAAAGTATTTAGTTGACTGGCTACTCTTCATGGAGGTAATATTAAATGGTCCCCTGCTATATT
ATGAGCCTTAGGCTTTTATTTTCCCATTTACCGTAGGAGGGCCTAACGGGGATTGTACTAGCAAACCTCT
TCACTAGACAATGTTCTTCACGGCACATATTACGTGGGGGGCCACTGTCACTATGGCTTGTCAATAGGG
GCAGTATTCGTATCATAGGGGGGTTTCGTCC

SEQ ID. NO.: 89

pKVC64B:

GCAATCCTGGCCTGGGGGCCTGAGGCCCTTCCCCTGCTCCAGGCTGTCATCTCCTGCCTCCTCTCCTCC
GGCCTCCTCAGTTTTGCCAACTGCAATTCATTTGAGTTACTGTTTATGCTAAGCATGTACTCCTGACTT
GTCATGACTTTTCTCTGGAGCAGGTGGCTAGAAAAAGAGGCTATGGGTGGGGGAAAAAATGTTCTTG
TTCTCACTTGTAAGGCTGGTTTTTTGGCTTTTCTGCCATGGGATTCTCCCCCTGACCTCTCCCCTCAGCA
ATTCCTGCAAAGGGTTAAAAATTTAACTGGTTTTTNACTACTGATGGACTTAAACAACACAAAGGATG
CTGGGATGCTAACTTGGTTAACTAAACCATCAAGGTTGTACCAAGTTTTGGATTGGTAACTGGTNAAT
ACAAGTA

FIGURE 5N

SEQ ID. NO.: 90

pKVC66B:

CGTATGAGGCAGTCCCCTGCTCGCCCCATCCCCACTGTCAGGTCTATGGGTCCGTGGGCCAGAATGGG
GTGGAATTGGGTTGAGGGAGGGACAGCCCTGGCTGACAATGATATTGGTGTAAATCAACATTAACCGAGC
CGGCTTCAGCTTACCTCAACCCGGGCAGGACACCACCACCTTGAGAAACCACAAGCTGGAGCGACCCCTC
AGGCCCTGCAGGCCCTTGCAAACAGCCCTGGGTGGACCCACACCAGTCCCTGTTAGCCAGCTAGGCCCA
GTCTTCCTTCAGCACCACACTTTTATCCTGGGCAGGTTTCTGTCAGGTGGAAGCTGGTAAAAGCGGGTC
CCAGCCAAGGGCTTCAGGTTGAGCGCCAGCCAGTAACCTCAATTCTTAACGGTGGGCAGGA

SEQ ID. NO.: 91

pKVC82B:

GCCACCTGACCCTCCTAACCCATGGCTGTCTGATGATACTACTTTCTGGGAACCTTGNAAGCAAGCAAAG
AACCAAGTCAGCAGAGGGTAAACGATGGGGTTTTGGCATGGATGAAGCATTGAAAGACCCAGTTGGGA
GAGAACAGTTTTCTTAAATTTCTAGAGTCAGAATTCAGCTCAGAAAATTTAAGATTCTGGCTAGNCAGTG
GAAGNACCTGAAAGNAAAAGGTCTAATNAGGAGAAAGTTCCCTTTCCCGGAGATTGAGGAAAATATGG
GCAAAGNAATTTTCTTGGGCTCCCTGGGAGGCTTCCCCAGNTGCCCAATCCAAACCTTGGGGTTTTCT
NAAGGAGGCTNATGGATT

SEQ ID. NO.: 92

pKVC110

GAGAAAGACATAATGGTTATGGCATTGGCTTGAAACCAGTTAAAGAGGGTTCGATTCCTTCCTTTCTTA
TTTTAATAGTACGTAAGTTGGCTCTTCAAATGTGTGGTACGGAGGAGGACATCcATGCAATCATTCAAG
ATTAGTTGTGGTTAATTCTACTATGGCCACTTCTCGCTTGA TGGCAAAGCTTCT

SEQ ID. NO.: 93

pKVC134: Homologous to human alpha tubulin; Accession HSHA44G

CCGCCAGTGTGCTCTAAAGTGTGGTACCCTGGTGGAGACCTGGCCAAAGTACAG
CGAGCTGTGTGCATGCTGAGCAACACCACAGCCATTGCTGAGGCCTGGGCTCGC
CTGGACCACAAGTTTGACCTGATGTATGCCAAGCGTGCCTTTGTTCACTGGTATGTGGGTGAGGGCATG
GAGGAAGGAGAGTTTTCTGAGGCCCGTGAGACATGGCTGCCCGTGAGACATGGCTGCCCTTGAGAAGGA
TTATAGGAGGTTGGTGTGGA

SEQ ID. NO.: 94

pKVC108: Homologous to Mouse Initiation factor eIF-4A;

Accession MMEIF4AL

TCTTCTCCCAAAAACACTAATCCATGTCCGTAACCCACTCAGCCTCCAGACCCAGAGGCTCTCCCCA
CCCAGCTGCCACCTCTAAAGAGGATTCAAGGGGCTATAGTGTcACCCAACCTCATTTGCTGGACCAAA
TCTGGAGAACCcTTGAGCTAGGTGGCCcATGGGgTTGTCCcAGGTGGGGgAGCAGGGGAGAGAAAATG
GTAGCCATTTTTACATTGTTTTGTATAGTATTT ATTGATTGAGG

FIGURE 50

SEQ ID. NO.: 95

pKVC105B: Homologous to Human mRNA for proliferating cell nuclear antigen associated protein;

Accession HSPAG

GTCAGACACAACCTTTCTGAATCCTCTNAGGANGGTGATCCAGTTCATGAANATTCTCTGTAAAATNANT
NTGGNAACTANATNAGTGNNGATNCAGGTCTNGAGNNTCTCCTTCCAGTGNCTAAAAAGTNCACAGAN
GNCAGGAACCTATCTGCATGCAGTCACCAAGTTCATNC TCTANGCA

SEQ ID. NO.: 96

pKVC92B: Human Mitochondrial hinge protein; Accession HSHINGE

CCCAGCCTTCATGAGCTGGTCATCAGGATACTTTCTTATGGGNTNGANCATGCCANTTGCTTNTNCGNG
TANATGTAAGTTCATGNCAACCNCATTTTTTTCTAGCCTNNGNCTNAAGGTNANTCGTCTCNTTANG
CAGCNGANNAGTTGNAGTCTNTCAAANGNNCACAANACCTAA

SEQ ID. NO.: 97

pKVC91: Homologous to Bovine NADH dehydrogenase; Accession MIBTXX

GGGTAAAGTGATAGGAGGAGAAGGGCTGAGTAGGTGGAGGCTATTAGGGCATTCTCGGTGTAAATG
ATGGGTGATATTTTAATGTGGTGTGTGATTTGCCTCGTTGAGTTATAATAAGTATGTAGAGGgaGT
ATaGccCTGTAATGATGATATTAGTACCCATTAGGATAATGGTTATGTTTGATCATGAGAAGGAGGCTA
TTACTAC

SEQ ID. NO.: 98

pKVC90: Homologous to Human hnRNP core protein A1; Accession HSRNPA1

ACAACCTTTGGCCGTGGAGGAACTTCAGTGGGCGAGGTGGCTTTGGCGGCAGTCGAGGTGGTGGTGGAT
ATGGTGGCAGTGGGGATGGCTATAACGGATTTGGTAACGATGGAAGCAACTTTGGAGGTGGTGGAAAGCT
ATAATGATTTTGGCAATTACAACAATCAATCTTCAAATTTTGACCCATGAAAGGAGGAAATTTTGGAG
GCAGAAGCTCTGGCCCCCTATGGTGGTGGAGGCCAATACTTT

SEQ ID. NO.: 99

pKVC86B: Homologous to Rat Ribosomal protein S27; Accession RRS27

GCGAAGGACCTCCTGCACACGTCCCCGGAAGAGGAGAAGAGGAAGCACAAGAAGAAGCGCCTGGTGCAG
AGCCCCAACTCCTACTTCATGGACGTGAAGTGCCCGGGTGCTACAAAATCACCACCGTGTTTCCCT

SEQ ID. NO.: 100

pKVC82: Human Carboxypeptidase E; Accession HSCARBE

ATCTGCCATTTTAGACTTAAAGGAAATATTCACGTGTTATTTACGATCCAGAAGTTTTTGAGTAATTC
TGGCTTTTAAAACTAATGAAGTCCTTTTAGTGTAATGGTAACAGTGCCACATAGTGAATGCCACTGAA
AAGGTCAACAGCTACATTTTGGTGTGTGAGCATTATACCGCAAGACTTACATAGTTCAGTATAA

FIGURE 5P

SEQ ID. NO.: 101

pKVC80: Homologous to Rat VAMP-2; Accession RNVAMPB

GGTCCTTGATCACTTTTCATTTGCATGACGTTCCCTGCAGGTGGTGGGAGCCTGGGCTTTTGGGGAGCC
AGAACCCTTCTGGCCCCCAGAATCACCCCTCCTAGCCCCCTCTAGTCCAGTTTGCCTCCCCTGCCCCCA
TTTTCCAAACCTCTTGTCCCTCCCCTCCCTCCCCCTCCCCCAGCTGGTGTGGAAGTGTCTCGGAG
TTCAGTGTGTATGAAGGACAATAGTTTGCACTGGAGTTT

SEQ ID. NO.: 102

pKVC79: Homologous to Bovine Nuclear encoded ADP/ATP transporter;

Accession BTADTPMT

GGATGATTGCCAGAGCGTGACAGCGGTGCGAGGGCTGGTGTCTACCCCTTTGACACTGTCCGCCGTA
GATGATGATGCAGTCTGGCCGAAAGGGGCGGATATTATGTACACTGGGACGGTGGACTGCTGGAGGAA
GATTGCAAAAGATGAGGGAGCCAAGGCTTTCTTCAAAGGTGCCTGGTCCAATGTGTTGAGAGGCATGGG
CGGAGCTTTCGTATTGG

SEQ ID. NO.: 103

pKVC59B: Homologous to Rat scg10; Accession SCG1_RAT

ACGACTCACTATCAGGGCGAATTGGGCCCTCTAGATGCATGCTCGAGCGGCCGCCAGTGTGGGAAAAGG
AGAGGCATGCCGCGGAGGTGCGCAGGAACAAGGAACCTCAGGTTGAACTGTCTGGCTGAAACGATGGAG
GGTATGGCAGCCCCACCATTAGTAAATCCCCCTGCCTATATTATAATGGTTCATGCGATATCAGTATG
GGAAATGTATGACATGGTTTAAAAAGAACTCATTATAAAAAACAAAAACAAAAAACAGAATC

SEQ ID. NO.: 104

pKVC55: Homologous to Human LAMP-1; Accession HSLAMP1A

AGCATGCTGATCCCCATTGCCGTGGGcGgCCTGCGGGGGCTGGTCCTCATCGTCCTCATTGCCTACCTC
ATCGGCAGGAAGAGGAGCCACGCGGTACCAGACGATCTAGCAGGGCTGCGACACGTGGGGCCGGCTGC
CACTTCCGGTCTCCGCTCGTCCCCTGAGCTTAGGTTGGCGTGGAGGGCGGCACGTTTCTTGCAAACCTG
ATTTTCAAATCTGCTTTATCCGATGTGAAGTTCATCTTGCAACATTTACTATGCACAAGAGTATTGAAA
TGAC

SEQ ID. NO.: 105

pKVC49B: Homologous to Chicken Contactin; Accession GGCONTAC

TTCATTATGAAAATATCAATAAATATGTCATTAGTTTACATTCAACTCTTTGTTATAAAATTAACCTTT
TTAATAATAAGTGAAATGGGTGATTTCCCCCTGGAGGGATGTCAACAGGCTTAAATCATTTCCTGGTT
TCATAAAATACAACTCCTTTGAAAAGGGACAAATCTCTTCATACTTTTGGGGAACGGATACTGTGT
AAGCCCTCTGTACAAAAGTTTGGGGTTTTTCATTGTTACACTTTGGGGTTTTCCCTTTTCAAGGGGCCCC
CCTGTGGGGGGTTTTTTTTTTATGCGGGCAACCAACTAAATTTTTTTTCCCAAATGGAATGCCCCGCC
TTTTTTTTTCTAATGTTTTTTTGCAATAAGGGGGGCCAAAACCGGGGAGGGTTTTTCCATGAAAAGGGT
TCCTTAAGGGTGAGGGGGAACACGCTTTGGGGGGGGTTTTCTTTTAAGTTTGTGGCCCCAGTAGGG
GGGAGAAAGCCCTCCCCCGGGAACAGGGTTTTGGTTCCCCACGG

FIGURE 5Q

SEQ ID. NO.: 106

pKVC47B: Homologous to Human 71 kD heat shock cognate protein;

Accession HSHSC70

CCTGAGAATAGGTCTAGCATTGTTCCACACAAAACATTTGAAGGACCCAAATTTGTAGCAAATTCCATG
GCAGTGAAGTTGAGCTGCTATAGTTAATAAACTGGGCATTCTTGATACTTGAATATGGAATATGTGCAC
AAGGGAAGTAAATACAACATTGCACTTTATAAGCACTGTATTGTTAAGTGGGAAATGCAATGTCTTTAA
AATAAACTGTATTTAAAATTGGCGCCCCAAAA AAAAA

SEQ ID. NO.: 107

pKVC46B: Homologous to Human 71 kD heat shock cognate protein;

Accession HSHSC70

CCTGAGAATAGGTCTAGCATTGTTCCACACAAAACATTTGAAGGACCCAAATTTGTAGCAAATTCCATG
GCAGTGAAGTTGAGCTGCTATAGTTAATAAACTGGGCATTCTTGATACTTGAATATGGAATATGTGCAC
AAGGAAAGTAAATACAACATTGCACTTTATAAGCACTGGTATTGTTAAGTGGGAAATGCAATGTGCTTA
AATAAACTGTATTTAAAATTGGCACCAA

SEQ ID. NO.: 108

pKVC35B: Homologous to Human Vacuolar proton ATPase channel;

Accession HSPCHSUCA

CTTTAGAGGACACACACNCACGGGGCCGCCGCCCCCAGTAGTCGGTCTTGTAATGCGCAGTGTCTTA
GTGCCCCGTTGTCTGCTACCCCGGCCTCGCCCCCGCCCCCGCCCGTGCCGTGGACATCCGGGGCCACTCC
TTACCCATCCGGGCCTCCGGCCCCCACTCATCTGCCCTAGAGCGCTCTGTAGAAGGGTGAATTAGAGTT
GTATTTCTCTTCACTGGATGTTTCTTATTTATA AAGATTTGATCTGTTC

SEQ ID. NO.: 109

pKVC27B: Homologous to Rat Cytoplasmic Succinyl CoA synthetase;

Accession RNGLTA

GCGACACGTTCTGTCAATTTATGTTCTCCTCCTTTTGCTGCTGCTGCCATCAATGAAGCTGTTGAGGCG
GAAATGCCCTTGTTGTGTGCATTACTGAAGGTATCCACAGCAGGACATGGTGCGGGTCAAGCACAAA
CTGCTGCGTCAGGGAAAGACCAGGCTGATCGGGCCTAACTGCCCTGGAGTGATCAATCCTGGAGAATGC
AAAATTGGCATCATGCTGGCCATATTCACAAGAAAGGAAGAGTTGGTATTGTGTCCAGATCTGGG

SEQ ID. NO.: 110

pKVC22: Homologous to Human clq beta isoform; Accession HSC1QBR

GGAAAGATGGGATTGTATGAAACACTGCATTTACAGCAAAGACCTCAGTCCAGAACACAACACAGGGG
ACCAAGTGGATTGAGGTGTGGTCAAACTCTGGGGATCACAGTGGGGATACCACCTCCAGGGCTGGTGA
CAGATTCAGGACCTCCTGGCACACCCGGGACCCAGGGATAAAAGGAGAGAAAGGGCTGCCAGGGCTG
GCTGGAGACCATGGCGAGTTTGGGGAGAAGGGA GACCAGGGATTCTGGAATCAGAAA

SEQ ID. NO.: 111

pKVC22B: Homologous to Human Phospholipase A2; Accession HUMPHPLA2

TTCCAGACGGGAGATTGATTGGAAAAAAGTAATGTGTTCCATTTAAAATTTTGGTATATGGCATTTT
CTGACTTAGGAAGCCACAATGTTTTTGTCTTGCCCATCATGACATTGGGTAGCATTAAGTTTTGTGC
TTCCAAATCACTTTTGTTTTAAAGATTTCTTGATCTTGTTATAGCCTGCCTTCAATTTTGATCTTTAT
TCTTTCTATTTGTCAGGTGTACAGGATTACCTT TTTTAGCCTTCTGTCTT

FIGURE 5R

ACCCTTTCTATGTGTTTTATCTAATTaTTTTGGTTGTTAATATGGTAATAATTTAAAGTCAAGGTAAA
TTTTAAATATTAAGATTTCTGATTTATTGAGCTTGACTTATGCCACCACGCTTATGTAAAATGAAAGTA
GCACCATGGTGAAACTGAAAAAGTTGCTCAGTTGTAAACAGTTTTGATTTATTCTTTCTTGACCTCT
TTCCCTTATTGTCTTGAACCATAGCAAAAGGATACTGCATCTCTTAATAATTGTAGTGCTGAGGTATT
GAaGTTATAT

pKVC18: Homologous to Human Cytochrome oxidase I; Accession MIHSCG
GTTATATTGACTCCTACAAACATAATCGTAAAGTGAATCTTTGCTCAAGTGTTGTCAAGGGTATATCCT
GAGAATAGGGGGAATCAATGGACGAAGCCTCCTATGATAGCGAATACTGCTCCTATTGACAAGACATAG
TGAAAGTGGGCCACTACGTAATATGTGTCGTGAAGAACAATG TCTAGTGAAGAGTTTGCTAGTACA

pKVC17B: Homologous to Rat SubstanceP receptor; Accession RNSPR05
GCTATAGACACAACTTTCACT
CACCA

pKVC12B: Homologous to Human 90 kD heat shock protein;
Accession HSHSP90R
ACGTCGTTTTCCAAAGAGAAGAGCGTTGTTTAGAGTAGCGAAATTCGAAGGCTGCTTAGGCGCATTGT
AAAGCTGTTGGGGAAATAACTCCACAAGTTTCGTGAGTGGAATGTAGTGCTCGAAACACATTCTGCTT
TAAAAGGTTGTAACAAATACAAACAAATTTAAAAAAGCTCTGACAAATGTTTTGTGTGGGAAGCGGG
GTTCCAAAATACAGGGCGGCCCC

pKVC10B: Homologous to Human Cytoskeletal gamma actin;
Accession HSACTCGR
TTGTCATCTCTTCAAGAATTGACAACAGATTTTGGTTTTCTACTGTCATGTGGAACATT
AGGCCCCAGCTTCGGCTCCTTGTGCGAGGAAAATAAA

FIGURE 5S

SEQ ID. NO.: 117

pKVC9: Homologous to Human v-fos transformation effector; Accession
HSFTE1A

GCATCTGATGGCCTTAAGGGTCGTGTGTTTGAAGTAAGCCTGGCTGATTTGCAGAATGATGAAGTTGCA
TTTAGGAAATTCAAGCTAATTACTGAAGATGTTTCAGGGCAAAAACCTGCCTGACTAATCTCCATGGCATG
GATCTTACCCGGGACAAAATGTGCTCCATGGTCAAAAATGGCAGACCATGATTGAAGCTCACGTTGAT
GTCAAACTACCGATGGGTATTTGCTTCGTCTCTTTTGTGTCGGTTTTACTAAAAACGCAACAATCAG
A

SEQ ID. NO.: 118

pKVC6B: Homologous to Chicken Amphiphysin; Accession GDAMPHIP

CCTTCCAGAACCCCTGAGGAGCAGGATGAAGGCTGGCTCATGGGCGTGAAGGAGAGTGACTGGAACCAGC
ACCTAGAGCTGGAGAAATGTCGGGGCGTCTTCCCCGAGAACTTCACCGAGCGGGTTCAGTGAGGGCAGC
AGCTGCTGAG

SEQ ID. NO.: 119

pKVC6: Homologous to Human TAPA-1; Accession HSTAPA1

TCTACGACCAGGCTTTGCAGCAGGCCGTGGTAGACGACGACGCCAACAAATGCCAAGGCCGTGGTGAAGA
CCTTCCATGAGACGCTCAACTGCTGTGGCTCCAGCAGCTCTCCGCGCTGACCACCTCCATTCTCAAGA
ACAACCTGTGTCCTTCAGGCAGCACTGTCATCAGCAACTTCTTCAAGGAGGACTGCCACCAGAAGATCG
ATGACCTCTTCTCGGGAAAGCTGTATCTCATTG GCAT

SEQ ID. NO.: 120

pKVC4B: Homologous to Rat alpha internexin; Accession#RNINTLAA

CACCTAAAGAGTTGCCAGGTCTCTGTACACATCTCCATTACAACAGATAGGGTGTGATGCTTTTACT
AACTTTCTTATCCTAGGACCTGCTGCAATGGTTCAAGGAACTGGAAAGATGCTTTCTTCTTCTCCTTt
CCCTCACTCCATCCCTGTCTTTACTCCTCAGACTTCCTGTAAACATTAGTAAGATAAGAATTAAGAGT
CACACGAATCCAC

SEQ. ID. NO.: 121

>pKVC154

ATTTGGCTCAGTGGCAGAGCGCTTGCTAGGAAGAGCAAGGCCCTGGGTTCGGTCCCCAGCTCCGpoly
(A)

SEQ. ID. NO.: 122

>pKVC159

GGGAGGAGGAGGAAGAGGAGGAAGGAGAGGAGGAGGAGGAGGCTGCAAAGGCTCTGGGCTCCTCTpoly
(A)

SEQ. ID. NO.: 123

>pKVC151

GTAATTATTGGCTCAACTTTTCTAATTGTCTGTCTACTACGACAACTAAAATTCCACTTCACATCAAAA
CATCATTTTCGGATTTGAAGCCGCAGCATGATACTGACACTTCGTAGATGTAGTTTGACTATTCCTATAC
GTTTCTATCTATTGATGAGGATCCTpoly(A)

FIGURE 5T

06301507 042899

SEQ. ID. NO.: 124

>pKVC158

GATTTGGAGAAGCCTTCGCATCAAAACGAGAAGTACGCTCAATTTCTACTCCTCAACTAACCTAGAAT
GACTGCATGGATGCCCCCACCCTACCACACATTGGAAGAACCTTCCTACGTAAAAGTTAAATAAGAAA
GGAAGGATTGGAACCCCTACAACCTGGTTTCAAGCCAATTTTCATAACCATTATGTCTTTCTCAATpoly
(A)

SEQ. ID. NO.: 125

>pKVC160

AAGGATAATGCTGTTTATTAATAAATACTCAGGAAGTCAGGGTATTGATGCAATTTTACATACGCACT
TGGGTAGTCTGAAGTTCCATTATTCCAGCAGTTTATATAAATGTTTCAGATCAAAAGAGAAAAGAAACA
CTTTACAGAGACCAGCAGTTGCTTATCAGTTTGGTCATGAGTCTGCTTGTAGTAAAAATAAACTCCCT
CTTGCAATTGCTGAAGAATGTCCTT

SEQ. ID. NO.: 126

>pKVC157

CAGCTCCCTAGTACTTTACTATTATTTCACTAATACTAACAACAAAACCTAACACACACAAGCACAATAG
ACGCCAAGAAGTAGAAACAATTTGAACAATCCTCCCAGCTGTCATTCTTATCCTAATTGCCCTTCCCT
CCCTACGAATTCTATACATAATAGACGAGATTAATAACCCAGTTCTAACAGTAAAACTATAGGACACC
AATGATACTGAAGCTATGAATATCTGACTATAAGACCTATGCTTTGACTCCTACATAATCCC

SEQ. ID. NO.: 127

>pKVC156

CCATGCTTGTGACAGACATACAGCCACTTCCAATAAGCAAGCCTCTGCTTCTGCTACCTGCATGGA
GCCCACTGTGACACTCAGACCATCCCCGGTCACTCACTCGTGTCTGAGAATCTCAGTGAGAGCTGCCTC
TGTCACGGACGGAAGCCAACACAGCCACCTCTCGACCTGGTCCCCACAGCACCCACCCTCCCTGCATG
CAGCTGTCCCTGCTAACCCCCAATGTTATGTTACACTGTGTAAATCCCCACTGCTGCCGTGTGTGGGTT
GTGTACGTCGTCATGTCCTGGTTTATAACTATGGTGCGGTCGGGAAGGATTCTGTAAATGCTGCTCTAA
GA

SEQ. ID. NO.: 128

>pKVC153

CCTAGACTCACAAGTCAAAGTAATACTAATATCTTATTGACCCAATTATTGATCAACGGACCAAGTTAC
CCTAGGGATAACAGCGCAATCCTATTTAAGAGTTTCATATCGACAATTAGGGTTTACGACCTCGATGTTG
GATCAGGACATCCCAATGGTGCAGAAGCTATTAATGGTTCGTTTGTTCACGATTAAAGTCCTACGTGA
TCTGAGTTCAGACCGGAGCAATCCAGGTCGGTTTCTATCTATTTACAATTTCTCCAGTACGAAAGGAC
AAGAGAAATGGAGCCTCCTTACCATAAGTGCTCCCAACCAATTTATGpoly(A)

SEQ. ID. NO.: 129

>pKVC152

GCTTCAATTTACTAGTTCAACTTATATAAAAACAACCTAATGGGCTAAAACAAAATAAATATGAACTAA
AAAATTTTCGGTTGGGGTGACCTCGGAGAATAAAAAATCCTCCGAATGATTTTAACCTAGACTCACAAGT
CAAAGTAATACTAATATCTTATTGACCCAATTATTGATCAACGGACCAAGTTACCCTAGGGATAACAGC
GCAATCCTATTTAAGAGTTTCATATCGACAATTAGGGCCCACGACCTCGATGTTGGATCAGGACATCCCA
ATGGTGCAGAAGCTATTAATGGTTCGTTTGTTCACGATTAAAGTCCTACGTGATCTGA

FIGURE 5U

SEQ. ID. NO.: 130

>pKVC161

AGAGATATCGGAACCCTCTACCTATTATTTGGAGCCTGAGCAGGAATAGTAGGGACAGCTTTAAGTATT
CTAATTCGAGCTGAACTAGGACAGCCAGGCGCACTCCTAGGAGATGACCAAATCTATAATGTCATCGTC
ACAGCCCATGCATTGTAATAATTTTCTTTATAGTAATACCTATAATAATTGGAGGCTTCGGGAACTGA
CTTGTACCACTAATAATTGGAGCCCCTGATATAGCATTCCCACGAATAAATAACATAAGCTTTTGACTG
CTTCCTCCATCATTCTACTCC

SEQ. ID. NO.: 131

>pKVC162

GAGCTGTTGCCAGTGTAAGACAGCAAACATGGACACTCTCGCACTGTGCATCACAAAGCTAACAAATC
GAAATCTTGAATGCAGTCTGTCCTAAGTCCAGGCAAGTGACAGCCATGTGTGTCTGCAGTGCTGTGTCA
CCACGTCCTGCATTGTTGGAGCTGCTGCAGGGACACTGAGATGAGCAGGTTCTTTGGAAAGAACTGTTG
TGCTCCTCAAAGCAGTGTTTCAGATTTTAAAGGTTCTTAGCCTCCTCAGTTCCTTATGTGGAAGTGTAGG
ATCCCCTTCATAAATTTTAAAGTGCTTATGTGATCCAATTGGTCTACATTTT

SEQ. ID. NO.: 132

>pKVC36BR

CTTTAGAGAAGGCAGGTCTTACAAACACTACAGAAAAGCCGTTTGGACGTAA
AAATCCAAGGAGAAAGGAGTCATTAGGAAATGTAAACATAGGACACAGAACG
CATGTTGTGTGATGGTCCCTTCTCTCCGTGTGGTTCCAGAATATGCTCCTGAC
CCCAGAGCCGCCACCTGAGCGCGCACCGGGAAGGTCACAGACGACTTCAGGC
TTCAGGCGCAACGTC

WW\MISC-7\2318SEQR\V2

FIGURE 5V

DECLARATION AND POWER OF ATTORNEY

As the below-named inventors, we declare that:

Our residences, post office addresses, and citizenships are as stated below under our names.

We believe we are the original, first, and joint inventors of the invention entitled "GENE SEQUENCES ASSOCIATED WITH NEURAL PLASTICITY AND METHODS RELATED THERETO," which is described and claimed in the specification and claims of patent application Serial No. 08/224,621, which we filed in the United States Patent and Trademark Office on April 5, 1994 and for which a patent is sought.

We have reviewed and understand the contents of the above-entitled specification, including the claims, as amended by any amendment specifically referred to herein (if any).

We acknowledge our duty to disclose information of which we are aware which is material to the examination of this application in accordance with 37 C.F.R. § 1.56(a).

We hereby appoint RICHARD W. SEED, Registration No. 16,557; ROBERT J. BAYNHAM, Registration No. 22,846; EDWARD W. BULCHIS, Registration No. 26,847; GEORGE C. RONDEAU, JR., Registration No. 28,893; DAVID H. DEITS, Registration No. 28,066; WILLIAM O. FERRON, JR., Registration No. 30,633; PAUL T. MEIKLEJOHN, Registration No. 26,569; DAVID J. MAKI, Registration No. 31,392; RICHARD G. SHARKEY, Registration No. 32,629; GEORGE B. FOX, Registration No. 31,510; DAVID V. CARLSON, Registration No. 31,153; MAURICE J. PIRIO, Registration No. 33,273; KARL R. HERMANNS, Registration No. 33,507; DAVID D. McMASTERS, Registration No. 33,963; ROBERT IANNUCCI, Registration No. 33,514; JOSHUA KING, Registration No. 35,570; MICHAEL J. DONOHUE, Registration No. 35,859; LORRAINE LINFORD, Registration No. 35,939; KEVIN J. CANNING, Registration No. 35,470; PATRICIA E. CHAMBERLAIN, Registration No. 37,038; CHRISTOPHER J. DALEY, Registration No. 34,807; TIMOTHY J. CREAN, Registration No. 37,116; STEVEN D. LAWRENZ, Registration No. 37,376; ROBERT G. WOOLSTON, Registration No. 37,263; MANYA S. DEEHR, Registration No. 37,120; CLARENCE T. TEGREENE, Registration No. 37,951; and TARA A. PHILLIPS,

08/224,621 20510260

Registration No. 35,980, composing the firm of SEED and BERRY, 6300 Columbia Center, Seattle, Washington 98104-7092, our attorneys to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. Please direct all telephone calls to Manya S. Deehr at (206) 622-4900 and telecopies to (206) 682-6031.

We further declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that the making of willfully false statements and the like is punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and may jeopardize the validity of any patent issuing from this patent application.




Max Cynader

Date

June 20/94

Residence : City of West Vancouver
Province of British Columbia
Citizenship : Canada
P.O. Address : 889 Farmleigh Road
West Vancouver, British Columbia
Canada V7S 1ZB



Shiv Prasad

Date

June 20, 1994

Residence : City of Vancouver
Province of British Columbia
Citizenship : India (Permanent Resident of Canada)
P.O. Address : Eye Care Center
2550 Willow Street
Vancouver, British Columbia
Canada V5Z 3N9

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Max Cynader and Shiv Prasad
Application No. : 08/224,621
Filed : April 5, 1994
For : GENE SEQUENCES ASSOCIATED WITH NEURAL
PLASTICITY AND METHODS RELATED THERETO

Examiner : Bruce Campbell
Art Unit : 1632
Docket No. : 230018.401
Date : April 27, 1999


Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

APPOINTMENT OF ASSOCIATE POWER OF ATTORNEY

Sir:

I, David J. Maki, attorney of record in the above-identified application, appoint as associate attorney Jane E. R. Potter, Registration No. 33,332, of the firm of Seed and Berry LLP, 6300 Columbia Center, 701 Fifth Avenue, Seattle, Washington 98104-7092.

Respectfully submitted,
Max Cynader and Shiv Prasad
SEED and BERRY LLP



David J. Maki
Registration No. 31,392

DDM:MWR:em

6300 Columbia Center
701 Fifth Avenue
Seattle, Washington 98104-7092
(206) 622-4900
Fax: (206) 682-6031